These terms and conditions govern your use of the website alphaminr.com and its related services.
These Terms and Conditions (“Terms”) are a binding contract between you and Alphaminr, (“Alphaminr”, “we”, “us” and “service”). You must agree to and accept the Terms. These Terms include the provisions in this document as well as those in the Privacy Policy. These terms may be modified at any time.
Your subscription will be on a month to month basis and automatically renew every month. You may terminate your subscription at any time through your account.
We will provide you with advance notice of any change in fees.
You represent that you are of legal age to form a binding contract. You are responsible for any
activity associated with your account. The account can be logged in at only one computer at a
time.
The Services are intended for your own individual use. You shall only use the Services in a
manner that complies with all laws. You may not use any automated software, spider or system to
scrape data from Alphaminr.
Alphaminr is not a financial advisor and does not provide financial advice of any kind. The service is provided “As is”. The materials and information accessible through the Service are solely for informational purposes. While we strive to provide good information and data, we make no guarantee or warranty as to its accuracy.
TO THE EXTENT PERMITTED BY APPLICABLE LAW, UNDER NO CIRCUMSTANCES SHALL ALPHAMINR BE LIABLE TO YOU FOR DAMAGES OF ANY KIND, INCLUDING DAMAGES FOR INVESTMENT LOSSES, LOSS OF DATA, OR ACCURACY OF DATA, OR FOR ANY AMOUNT, IN THE AGGREGATE, IN EXCESS OF THE GREATER OF (1) FIFTY DOLLARS OR (2) THE AMOUNTS PAID BY YOU TO ALPHAMINR IN THE SIX MONTH PERIOD PRECEDING THIS APPLICABLE CLAIM. SOME STATES DO NOT ALLOW THE EXCLUSION OR LIMITATION OF INCIDENTAL OR CONSEQUENTIAL OR CERTAIN OTHER DAMAGES, SO THE ABOVE LIMITATION AND EXCLUSIONS MAY NOT APPLY TO YOU.
If any provision of these Terms is found to be invalid under any applicable law, such provision shall not affect the validity or enforceability of the remaining provisions herein.
This privacy policy describes how we (“Alphaminr”) collect, use, share and protect your personal information when we provide our service (“Service”). This Privacy Policy explains how information is collected about you either directly or indirectly. By using our service, you acknowledge the terms of this Privacy Notice. If you do not agree to the terms of this Privacy Policy, please do not use our Service. You should contact us if you have questions about it. We may modify this Privacy Policy periodically.
When you register for our Service, we collect information from you such as your name, email address and credit card information.
Like many other websites we use “cookies”, which are small text files that are stored on your computer or other device that record your preferences and actions, including how you use the website. You can set your browser or device to refuse all cookies or to alert you when a cookie is being sent. If you delete your cookies, if you opt-out from cookies, some Services may not function properly. We collect information when you use our Service. This includes which pages you visit.
We use Google Analytics and we use Stripe for payment processing. We will not share the information we collect with third parties for promotional purposes. We may share personal information with law enforcement as required or permitted by law.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Commission File Number: 001-33072
|
|
|
|
Leidos Holdings, Inc.
|
|
|
|
(Exact name of registrant as specified in its charter)
|
|
|
Delaware
|
|
20-3562868
|
|
(State or other jurisdiction of incorporation or organization)
|
|
(I.R.S. Employer Identification No.)
|
|
|
|
|
|
11951 Freedom Drive, Reston, Virginia
|
|
20190
|
|
(Address of principal executive offices)
|
|
(Zip Code)
|
|
|
|
|
|
(571) 526-6000
|
||
|
(Registrant's telephone number, including area code)
|
||
|
Title of each class
|
|
Name of each exchange on which registered
|
|
Leidos Holdings, Inc. Common Stock, Par Value $.0001 Per Share
|
|
New York Stock Exchange
|
|
|
|
Page
|
|
|
|
|
|
|
|
|
|
Item 1.
|
||
|
|
|
|
|
Item 1A.
|
||
|
|
|
|
|
Item 1B.
|
||
|
|
|
|
|
Item 2.
|
||
|
|
|
|
|
Item 3.
|
||
|
|
|
|
|
Item 4.
|
||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Item 5.
|
||
|
|
|
|
|
Item 6.
|
||
|
|
|
|
|
Item 7.
|
||
|
|
|
|
|
Item 7A.
|
||
|
|
|
|
|
Item 8.
|
||
|
|
|
|
|
Item 9.
|
||
|
|
|
|
|
Item 9A.
|
||
|
|
|
|
|
Item 9B.
|
||
|
|
|
|
|
|
|
|
|
|
|
|
|
Item 10.
|
||
|
|
|
|
|
Item 11.
|
||
|
|
|
|
|
Item 12.
|
||
|
|
|
|
|
Item 13.
|
||
|
|
|
|
|
Item 14.
|
||
|
|
|
|
|
|
|
|
|
|
|
|
|
Item 15.
|
||
|
|
|
|
|
Item 16.
|
||
|
|
|
|
|
•
|
Surveillance and Reconnaissance –
We offer a wide range of technologies in multiple domains that address the nation's most critical threats and deliver solutions to the U.S. Intelligence Community, DoD and military services. A primary focus is on the DoD's technology organizations, which include the Defense Advanced Research Projects Agency, Army Research Lab, Air Force Research Lab and Office of Naval Research. Our market concentration is on airborne and ground ISR, maritime systems, electronic warfare systems, distributed sensor systems, autonomous systems and command and control. We provide multi-spectral, airborne, ground and maritime ISR collection and processing systems, advanced sensor design, command and control solutions and training systems.
|
|
•
|
Enterprise IT and Integrated Systems –
We offer extensive software development capabilities for intelligence and information systems and deliver mission and enterprise-level solutions to the U.S. and allied Intelligence Community, DoD, military services, DHS and the Australian Department of Defense. Our markets include cybersecurity, data analytics, enterprise IT and operations and logistics. Our cybersecurity solutions detect and manage the most sophisticated cyber threats. We offer innovative data analytics capabilities, and we design, develop, integrate, deploy and support information-centric software and enterprise IT systems for complex, data-driven national security challenges. Our operations and logistics offerings include enterprise platforms that speed the supply chain of highly complex systems.
|
|
•
|
Global Services –
We provide high-end services to the U.S. Intelligence Community, DoD and federal civilian agencies. Operating around the world daily, we provide intelligence analysis, operational support, security, linguistics and training. In addition, we deliver tailored IT services and solutions to our customers across the globe.
|
|
•
|
Aviation Solutions –
Leidos is a trusted systems integrator serving Air Navigation Service Providers including the FAA, the Transportation Security Administration ("TSA") and airport operators. Our work in airport modernization helps stakeholders achieve stated objectives, including increased operational efficiency and safety, a technology enhanced passenger experience, non-aeronautical revenue enablement and state-of-the-art situational awareness and security. Leidos air traffic control systems are used in Air Navigation Service Provider facilities that control more than 60 percent of the world's air traffic. We work diligently to support the FAA's NextGen program with government accepted systems including En Route Automation Modernization, Advanced Technology Oceanic Procedures, Time Based Flow Management and Terminal Flight Data Management. For the National Air Traffic Services system in the U.K., we offer the SkyLine Air Traffic Management suite to enhance safety, improve on-time performance and increase fuel efficiency.
|
|
•
|
Security Products –
Our Vehicle and Cargo Inspection Systems enable the rapid scanning of vehicles and cargo using patented technology that produces a high-quality image using a low radiation dose while using less space and processing higher volumes of cars and trucks than other scanning systems. Our Reveal line of explosive detection systems for checked airline baggage pioneered the "reduced size" segment of this market with small, flexible systems that can be installed at airport check-in counters. We also have a line of radiation detection systems, which are used today at ports, border crossings and industrial facilities around the world – including most ports and border crossings in the United States.
|
|
•
|
Enterprise IT Services –
We deliver secure, user-centric IT solutions in cloud computing, mobility, application modernization, DevOps, data center and network modernization, asset management, help desk operations and digital workplace enablement
.
We help our customers achieve their missions and business goals by delivering purpose-built solutions, cybersecurity as a standard, efficient project delivery and end-user satisfaction. Leidos is modernizing enterprise IT for CONUS/OCONUS programs in classified and unclassified environments, including programs with the General Services Administration ("GSA"), the Department of Housing and Urban Development and the Department of Justice.
|
|
•
|
Federal Environment and Infrastructure –
We are trusted by civilian and defense agencies with substantial environmental and sustainability driven missions. Our pedigree across environmental management, nuclear security, energy efficiency, infrastructure management, mission support and IT modernization provides the applicable expertise needed to transform operations while modernizing aging infrastructure and maintaining environmental stewardship. We support several of the Department of Energy's largest nuclear production, operations and remediation sites. At Hanford, we provide site-wide infrastructure management and operation including oversight of land and logistics, public works, information technology, fleet transportation, environmental sustainability and compliance, first responder services and future project planning. Our environmental engineers and scientists address all aspects of remediation for soil, groundwater, surface water and sediment, including removal, treatment, bioremediation, containment, resource management, land use and institutional controls, air emission control and monitoring and remedy performance monitoring and reviews, including National Emergency Rapid Response.
|
|
•
|
Logistics –
Leidos is a global leader in large-scale, complex operations and logistics. Our programs extend from the bottom of the world on the Antarctic ice to the orbiting outpost that is the International Space Station. Our expertise goes beyond supply sourcing, shipping, warehousing and maintenance as we also provide systems engineering, specialized product support, training and field readiness, base operations, data analytics and software development. We are helping our customers, including the United Kingdom Ministry of Defence ("U.K. MoD"), the National Science Foundation ("NSF") and the National Aeronautics and Space Administration ("NASA"), streamline logistics through data analytics so more of their budgets can be applied to their mission activities.
|
|
•
|
Complex Systems Integration
– Leidos employs whole-systems thinking in fielding applied technology solutions across the entire continuum of care. We are working as the lead systems integrator deploying the next generation electronic health records system to DoD hospitals and treatment facilities worldwide, responsible for architecture, cyber and complex systems integration. We provide information technology solutions to the VA, National Institutes of Health, DoD and other government customers. Commercially, we are one of the largest systems integration and staff support firms for hospitals deploying modern electronic health records, and combined with our federal work, Leidos has a significant presence in electronic health record implementation, optimization and support. In addition, we provide consulting, platform integration services and support across a broad range of health operational activities including value based care enablement solutions, IT strategy, revenue cycle management, accountable care transformation, risk management, technology infrastructure and project management. Our teams are staffed with clinical subject matter experts who draw upon their deep experience and knowledge of healthcare and IT systems.
|
|
•
|
Managed Health Services
– We deploy a national footprint of health clinics and health providers to support care delivery services, including medical disability examinations for the Veterans Administration (including behavioral assessments), as well as serving other independent medical exam markets. We have developed unique capabilities in behavioral health management through many decades of experience with a special emphasis on substance abuse services. Our managed health services activities leverage our IT and mission enablement capabilities which underpin solutions we offer to our customers across all of our served markets.
|
|
•
|
Enterprise IT Transformation
– We manage the entire lifecycle of the IT journey for our customers. Our expertise includes IT strategic planning, outsourcing and management of large scale data centers, agile software development and system transformation, cloud migration and application modernization, digitization and advanced analytics. Our customers include the Centers for Medicare & Medicaid Services, Food and Drug Administration, Social Security Administration, VA and commercial customers. Leidos helps transform our customers' IT environments in support of their most critical missions. All of this is accomplished in a highly secure manner by leveraging our cybersecurity capabilities.
|
|
•
|
Life Sciences –
We provide life science research and development support to the National Institutes of Health, Center for Disease Control, Army Medical Research community, commercial biotech companies and the Frederick National Laboratory for Cancer Research, where we employ approximately
2,300
scientists, technicians, administrators and support staff. Our professionals operate a wide range of leading-edge research and development laboratories in the areas of genetics and genomics, proteins and proteomics, advanced biomedical computing and information technology, biopharmaceutical development and manufacturing, nanotechnology characterization and clinical trials management.
|
|
|
|
Year Ended
|
|||||||
|
|
|
December 28,
2018 |
|
December 29,
2017 |
|
December 30,
2016 |
|||
|
U.S. Government
|
|
85
|
%
|
|
84
|
%
|
|
81
|
%
|
|
U.S. DoD
|
|
47
|
%
|
|
47
|
%
|
|
56
|
%
|
|
U.S. Army
|
|
13
|
%
|
|
13
|
%
|
|
14
|
%
|
|
•
|
Definitive Award Contracts. U.S. government agencies may procure services and products through single definitive award contracts which specify the scope of services or products purchased and identify the contractor that will provide the specified services or products. When an agency has a requirement, the agency will issue a solicitation or request for proposal to which interested contractors can submit a proposal. The bidding and selection process can take a year or more to complete. For the contractor, this method of contracting may provide greater certainty of the timing and amounts to be received at the time of contract award because it generally results in the customer contracting for a specific scope of services or products from the single definitive successful awardee.
|
|
•
|
Indefinite Delivery/Indefinite Quantity ("IDIQ") Contracts. The U.S. government uses IDIQ contracts to obtain commitments from contractors to provide certain services or products on pre-established terms and conditions. The U.S. government then issues task orders under the IDIQ contracts to purchase the specific services or products it needs. IDIQ contracts are awarded to one or more contractors following a competitive procurement process. Under a single-award IDIQ contract, all task orders under that contract are awarded to one pre-established contractor. Under a multiple-award IDIQ contract, task orders can be awarded to any of the pre-established contractors, which can result in further limited competition for the award of task orders. Multiple-award IDIQ contracts that are open for any government agency to use for procurement are commonly referred to as "government-wide acquisition contracts." IDIQ contracts often have multi-year terms and unfunded ceiling amounts, therefore enabling, but not committing, the U.S. government to purchase substantial amounts of services or products from one or more contractors. At the time an IDIQ contract is awarded (prior to the award of any task orders), a contractor may have limited or no visibility as to the ultimate amount of services or products that the U.S. government will purchase under the contract, and in the case of a multiple-award IDIQ, the contractor from which such purchases may be made.
|
|
•
|
U.S. GSA Schedule Contracts. The GSA maintains listings of approved suppliers of services and products with agreed-upon prices for use throughout the U.S. government. In order for a company to provide services under a GSA Schedule contract, a company must be pre-qualified and awarded a contract by the GSA. When an agency uses a GSA Schedule contract to meet its requirements, the agency, or the GSA on behalf of the agency, conducts the procurement. The user agency, or the GSA on its behalf, evaluates the user agency’s requirements and initiates a competition limited to GSA Schedule qualified contractors. GSA Schedule contracts are designed to provide the user agency with reduced procurement time and lower procurement costs. Similar to IDIQ contracts, at the time a GSA Schedule contract is awarded, a contractor may have limited or no visibility as to the ultimate amount of services or products that the U.S. government will purchase under the contract.
|
|
•
|
Cost-reimbursement contracts include cost-plus-fixed-fee, award-fee and incentive
-
fee contracts. These contracts provide for reimbursement of our direct contract costs and allocable indirect costs, plus a fee. These contracts are generally used when uncertainties involved in contract performance do not permit costs to be estimated with sufficient accuracy to use a fixed-price contract. Cost-reimbursement contracts generally subject us to lower risk but generally require us to use our best efforts to accomplish the scope of the work within a specified time and budget. Award and incentive fees are generally based on performance criteria such as cost, schedule, quality and/or technical performance. Award fees are determined and earned based on customer evaluation of the company's performance against contractual criteria. Incentive fees that are based on cost provide for an initially negotiated fee to be adjusted later, typically using a formula to measure performance against the associated criteria, based on the relationship of total allowable costs to total target costs.
|
|
•
|
Fixed-price-incentive-fee ("FP-IF") contracts are substantially similar to cost-plus-incentive-fee contracts except they require specified targets for cost and profit, price ceiling (but not a profit ceiling or floor) and profit adjustment formula. Under an FP-IF contract, the allowable costs incurred are eligible for reimbursement but are subject to a cost-share arrangement, which affects profitability. Generally, if our costs exceed the contract target cost or are not allowable under the applicable regulations, we may not be able to obtain reimbursement for all costs and may have our fees reduced or eliminated.
|
|
•
|
Time-and-materials ("T&M") contracts typically provide for negotiated fixed hourly rates for specified categories of direct labor plus reimbursement of other direct costs. This type of contract is generally used when there is uncertainty about the extent or duration of the work to be performed by the contractor at the time of contract award or it is not possible to anticipate costs with any reasonable degree of confidence. On T&M contracts, we assume the risk of providing appropriately qualified staff to perform these contracts at the hourly rates set forth in the contracts over the period of performance of the contracts.
|
|
•
|
Fixed-price-level-of-effort ("FP-LOE") contracts are substantially similar to T&M contracts except they require a specified level of effort over a stated period of time on work that can be stated only in general terms. This type of contract is generally used when the contractor is required to perform an investigation or study in a specific research and development area and to provide a report showing the results achieved based on the level of effort. Payment is based on the effort expended rather than the results achieved.
|
|
•
|
Firm-fixed-price ("FFP") contracts provide for a fixed price for specified products, systems and/or services. This type of contract is generally used when the government acquires products and services on the basis of reasonably definitive specifications and which have a determinable fair and reasonable price. These contracts offer us potential increased profits if we can complete the work at lower costs than planned. While FFP contracts allow us to benefit from cost savings, these contracts also increase our exposure to the risk of cost overruns.
|
|
•
|
require certification and disclosure of all cost and pricing data in connection with certain contract negotiations;
|
|
•
|
define allowable and unallowable costs and otherwise govern our right to reimbursement under various cost-type U.S. government contracts;
|
|
•
|
require compliance with U.S. government Cost Accounting Standards ("CAS");
|
|
•
|
require reviews by the Defense Contract Audit Agency ("DCAA"), Defense Contract Management Agency ("DCMA") and other U.S. government agencies of compliance with government requirements for a contractor’s business systems;
|
|
•
|
restrict the use and dissemination of and require the protection of unclassified contract-related information and information classified for national security purposes and the export of certain products and technical data; and
|
|
•
|
require us not to compete for work if an actual or potential organizational conflict of interest, as defined by these laws and regulations, related to such work exists and/or cannot be appropriately mitigated, neutralized or avoided.
|
|
•
|
the FAR and supplements, which regulate the formation, administration and performance of U.S. government contracts;
|
|
•
|
the Truth in Negotiations Act, which requires certification and disclosure of cost and pricing data in connection with certain contract negotiations;
|
|
•
|
the Procurement Integrity Act, which regulates access to competitor bid and proposal information and government source selection information and our ability to provide compensation to certain former government officials;
|
|
•
|
the Civil False Claims Act, which provides for substantial civil penalties for violations, including for submission of a false or fraudulent claim to the U.S. government for payment or approval; and
|
|
•
|
the U.S. government CAS, which imposes accounting requirements that govern our right to reimbursement under certain cost-based U.S. government contracts.
|
|
•
|
we may not be able to identify, compete effectively for or complete suitable acquisitions and investments at prices we consider attractive;
|
|
•
|
we may not be able to accurately estimate the financial effect of acquisitions and investments on our business, and we may not realize anticipated synergies or acquisitions may not result in improved operating performance;
|
|
•
|
we may encounter performance problems with acquired technologies, capabilities and products, particularly with respect to those that are still in development when acquired;
|
|
•
|
we may have trouble retaining key employees and customers of an acquired business or otherwise integrating such businesses, such as incompatible accounting, information management or other control systems, which could result in unforeseen difficulties;
|
|
•
|
we may assume material liabilities that were not identified as part of our due diligence or for which we are unable to receive a purchase price adjustment or reimbursement through indemnification;
|
|
•
|
we may assume legal or regulatory risks, particularly with respect to smaller businesses that have immature business processes and compliance programs;
|
|
•
|
acquired entities or joint ventures may not achieve expected business growth or operate profitably, which could adversely affect our operating income or operating margins, and we may be unable to recover investments in any such acquisitions;
|
|
•
|
acquisitions, investments and joint ventures may require us to spend a significant amount of cash or to issue capital stock, resulting in dilution of ownership; and
|
|
•
|
we may not be able to effectively influence the operations of our joint ventures, or we may be exposed to certain liabilities if our joint venture partners do not fulfill their obligations.
|
|
•
|
Our certificate of incorporation provides that our bylaws and certain provisions of our certificate of incorporation may be amended by only two-thirds or more voting power of all of the outstanding shares entitled to vote. These supermajority voting requirements could impede our stockholders’ ability to make changes to our certificate of incorporation and bylaws.
|
|
•
|
Our certificate of incorporation contains certain supermajority voting provisions, which generally provide that mergers and certain other business combinations between us and a related person be approved by the holders of securities having at least
80%
of our outstanding voting power, as well as by the holders of a majority of the voting power of such securities that are not owned by the related person.
|
|
•
|
Our stockholders may not act by written consent. As a result, a holder, or holders, controlling a majority of our capital stock are limited in their ability to take certain actions other than in connection with its annual stockholders' meeting or a special meeting called at the request of qualified stockholders as provided in our certificate of incorporation and bylaws.
|
|
•
|
Our Board of Directors may issue, without stockholder approval, shares of undesignated preferred stock. The ability to authorize undesignated preferred stock makes it possible for our Board of Directors to issue preferred stock with voting or other rights or preferences that could impede the success of any attempt to acquire us.
|
|
•
|
developments in the U.S. government defense budget, including budget reductions, sequestration, implementation of spending limits or changes in budgetary priorities, or delays in the U.S. government budget process or approval of raising the debt ceiling;
|
|
•
|
delays in the U.S. government contract procurement process or the award of contracts and delays or loss of contracts as a result of competitor protests;
|
|
•
|
changes in U.S. government procurement rules, regulations and practices;
|
|
•
|
our compliance with various U.S. government and other government procurement rules and regulations;
|
|
•
|
governmental reviews, audits and investigations of our company;
|
|
•
|
our ability to effectively compete and win contracts with the U.S. government and other customers;
|
|
•
|
our reliance on information technology spending by hospitals/healthcare organizations;
|
|
•
|
our reliance on infrastructure investments by industrial and natural resources organizations;
|
|
•
|
energy efficiency and alternative energy sourcing investments;
|
|
•
|
investments by U.S. government and commercial organizations in environment impact and remediation projects;
|
|
•
|
our ability to attract, train and retain skilled employees, including our management team, and to obtain security clearances for our employees;
|
|
•
|
our ability to accurately estimate costs associated with our FFP and other contracts;
|
|
•
|
resolution of legal and other disputes with our customers and others or legal or regulatory compliance issues;
|
|
•
|
cybersecurity, data security or other security threats, system failures or other disruptions of our business;
|
|
•
|
our ability to effectively acquire businesses and make investments;
|
|
•
|
our ability to maintain relationships with prime contractors, subcontractors and joint venture partners;
|
|
•
|
our ability to manage performance and other risks related to customer contracts;
|
|
•
|
the failure of our inspection or detection systems to detect threats;
|
|
•
|
the adequacy of our insurance programs designed to protect us from significant product or other liability claims;
|
|
•
|
our ability to manage risks associated with our international business;
|
|
•
|
exposure to lawsuits and contingencies associated with Lockheed Martin’s IS&GS business;
|
|
•
|
our ability to declare future dividends based on our earnings, financial condition, capital requirements and other factors, including compliance with applicable law and our agreements;
|
|
•
|
our ability to grow our commercial health and infrastructure businesses, which could be negatively affected by budgetary constraints faced by hospitals and by developers of energy and infrastructure projects;
|
|
•
|
for acquisitions that we agree to but are unable for regulatory or other reasons to consummate, we may incur break-up fees; and
|
|
•
|
our ability to execute our business plan and long-term management initiatives effectively and to overcome these and other known and unknown risks that we face.
|
|
Location
|
|
Number of
buildings |
|
Square
footage |
|
Acreage
|
|||
|
Gaithersburg, Maryland
|
|
1
|
|
|
542,000
|
|
|
44.8
|
|
|
Columbia, Maryland
|
|
1
|
|
|
95,000
|
|
|
7.3
|
|
|
Orlando, Florida
|
|
1
|
|
|
85,000
|
|
|
8.5
|
|
|
Oak Ridge, Tennessee
|
|
1
|
|
|
83,000
|
|
|
8.4
|
|
|
Reston, Virginia
|
|
1
|
|
|
62,000
|
|
|
2.6
|
|
|
Name of officer
|
|
Age
|
|
Position(s) with the company and prior business experience
|
|
Roger A. Krone
|
|
62
|
|
Mr. Krone has served as Chief Executive Officer since July 2014. Mr. Krone is also Chairman of the Board. He brings more than 37 years of operational, strategic and financial execution experience for some of the nation’s most prominent names in aerospace. Mr. Krone has held senior program management and finance positions at The Boeing Company, McDonnell Douglas Corp. and General Dynamics. Mr. Krone is currently a member of the Georgia Tech Foundation Board of Trustees. He is a long-time supporter of the Urban League and currently serves on the board of the Greater Washington chapter. He is also a member of the Executive Council of the Aerospace Industries Association and a member of the AOPA Foundation's Board of Visitors.
|
|
Name of officer
|
|
Age
|
|
Position(s) with the company and prior business experience
|
|
James C. Reagan
|
|
60
|
|
Mr. Reagan has served as Executive Vice President and Chief Financial Officer since July 2015. Prior to joining Leidos, from 2012 to 2015, Mr. Reagan was with Vencore, Inc. (formerly The SI Organization, Inc.), a provider of information solutions and engineering and analysis services to the U.S. Intelligence Community, DoD and federal and civilian agencies, where he served as Senior Vice President and Chief Financial Officer. From 2011 to 2012, Mr. Reagan was Executive Vice President and Chief Financial Officer of PAE, Inc., a provider of mission support services to the U.S. government. Mr. Reagan is a Certified Public Accountant.
|
|
Ranjit S. Chadha
|
|
48
|
|
Mr. Chadha has served as Senior Vice President, Chief Accounting Officer and Controller since April 2016, and before that, as Assistant Controller. Prior to joining Leidos, Mr. Chadha spent six years at CSC (now DXC), and during his tenure there held several roles with progressive responsibility, most recently as an Assistant Controller at CSC. Prior to CSC, he spent 17 years at PwC, including two years in the firm's National Office Assurance Quality Group. He is a Certified Public Accountant as well as a Chartered Accountant from India.
|
|
Paul O. Engola
|
|
47
|
|
Mr. Engola has served as Senior Vice President, Chief Human Resources Officer and Head of Business Partnerships since January 2019, and before that, as Chief Administrative Officer and Deputy President, Defense and Intelligence Group. Prior to joining Leidos, Mr. Engola served Lockheed Martin Corporation for more than 10 years, most recently as Vice President, Transportation & Financial Solutions in their former Information Systems & Global Solutions business.
|
|
Gerard A. Fasano
|
|
53
|
|
Mr. Fasano has served as Executive Vice President and President, Defense Group since October 2018, and before that, as Chief Business Development Strategy Officer. Prior to joining Leidos, Mr. Fasano served Lockheed Martin Corporation for over 30 years in several capacities, most recently as a Vice President and General Manager in their former Information Systems & Global Solutions business.
|
|
Angela L. Heise
|
|
44
|
|
Ms. Heise has served as President, Civil Group since August 2016 when she joined Leidos. Prior to joining Leidos, Ms. Heise served as Vice President of Commercial Cyber for Lockheed Martin Corporation's former Information Systems & Global Solutions business.
|
|
Jerald S. Howe, Jr.
|
|
63
|
|
Mr. Howe has served as Executive Vice President and General Counsel since July 2017. Prior to joining Leidos, Mr. Howe was a partner at Fried, Frank, Harris, Shriver & Jacobson LLP, where he served in the firm’s government contracts, mergers and acquisitions, and aerospace and defense practices. Prior to joining Fried Frank, Mr. Howe held general counsel positions at TASC, a leading aerospace and defense company, and at Veridian Corporation, a publicly traded company that provided advanced technology services and solutions to the intelligence community, military and homeland defense agencies.
|
|
Mary V. Schmanske
|
|
56
|
|
Ms. Schmanske has served as Senior Vice President and President, Intelligence Group since October 2018, and before that, as Chief Administrative Officer and Deputy President and Chief Operations Officer, Health Group. Prior to joining Leidos, Ms. Schmanske served Lockheed Martin Corporation in several capacities, most recently as Vice President of Operations for programs under strategic review, Civil, Defense & Intelligence Solutions.
|
|
Jonathan W. Scholl
|
|
57
|
|
Mr. Scholl has served as President, Health Group since August 2016, and before that, as President, Health and Infrastructure Group. Prior to joining Leidos, Mr. Scholl served for five years as the Chief Strategy Officer for Texas Health Resources, one of the largest nonprofit health care delivery systems in the country. Prior to that, he spent 15 years with The Boston Consulting group and served as head of their North American Healthcare Provider Practice and leader of their Lean Six Sigma initiative for hospitals. He also served as Vice President for Applications Development for the TenFold HealthCare Group in Dallas. Mr. Scholl served five years in the U.S. Navy as a nuclear submarine officer and nuclear power plant instructor.
|
|
Period
|
|
Total Number of Shares Purchased (1) |
|
Average Price Paid per Share |
|
Total Number of
Shares Purchased as Part of Publicly Announced Repurchase Plans or Programs |
|
Maximum Number of Shares that May Yet Be Purchased Under the Plans or Programs |
|||||
|
September 29, 2018 - September 30, 2018
|
|
—
|
|
|
$
|
—
|
|
|
—
|
|
|
17,535,284
|
|
|
October 1, 2018 - October 31, 2018
(2)
|
|
3,347,602
|
|
|
63.18
|
|
|
3,345,876
|
|
|
14,189,408
|
|
|
|
November 1, 2018 - November 30, 2018
|
|
8,504
|
|
|
64.82
|
|
|
—
|
|
|
14,189,408
|
|
|
|
December 1, 2018 - December 28, 2018
(2)
|
|
690,720
|
|
|
63.18
|
|
|
690,674
|
|
|
13,498,734
|
|
|
|
Total
|
|
4,046,826
|
|
|
$
|
63.18
|
|
|
4,036,550
|
|
|
|
|
|
(1)
|
The total number of shares purchased includes shares surrendered to satisfy statutory tax withholdings obligations related to vesting of restricted stock units.
|
|
(2)
|
In October 2018, we entered into an Accelerated Share Repurchase agreement with a financial institution, whereby we paid an aggregate of
$250 million
and received approximately
4.0 million
shares of Leidos outstanding shares of common stock during the fourth quarter of fiscal 2018. All shares delivered were immediately retired. See "
Note 18—Earnings Per Share
" of the notes to the consolidated financial statements contained within this Annual Report on Form 10-K for further information.
|
|
|
|
12 Months Ended
(1)
|
|
11 Months Ended
(1)
|
|
12 Months Ended
(1)
|
||||||||||||||
|
|
|
December 28, 2018
(2)
|
|
December 29, 2017
(3)
|
|
December 30, 2016
(4)
|
|
January 1, 2016
(5)
|
|
January 30, 2015
(6)
|
||||||||||
|
|
|
(in millions, except for per share amounts)
|
||||||||||||||||||
|
Consolidated Statement of Income (Loss) Data:
|
|
|
|
|
|
|
|
|
|
|
||||||||||
|
Revenues
|
|
$
|
10,194
|
|
|
$
|
10,170
|
|
|
$
|
7,043
|
|
|
$
|
4,712
|
|
|
$
|
5,063
|
|
|
Operating income (loss)
|
|
749
|
|
|
559
|
|
|
417
|
|
|
320
|
|
|
(214
|
)
|
|||||
|
Income (loss) from continuing operations
|
|
582
|
|
|
364
|
|
|
246
|
|
|
243
|
|
|
(330
|
)
|
|||||
|
(Loss) income from discontinued operations, net of taxes
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(1
|
)
|
|
7
|
|
|||||
|
Net income (loss)
|
|
582
|
|
|
364
|
|
|
246
|
|
|
242
|
|
|
(323
|
)
|
|||||
|
Less: net income (loss) attributable to non-controlling interest
|
|
1
|
|
|
(2
|
)
|
|
2
|
|
|
—
|
|
|
—
|
|
|||||
|
Net income (loss) attributable to Leidos Holdings, Inc.
|
|
$
|
581
|
|
|
$
|
366
|
|
|
$
|
244
|
|
|
$
|
242
|
|
|
$
|
(323
|
)
|
|
Earnings (loss) per share:
|
|
|
|
|
|
|
|
|
|
|
||||||||||
|
Basic:
|
|
|
|
|
|
|
|
|
|
|
||||||||||
|
Income (loss) from continuing operations attributable to Leidos common stockholders
|
|
$
|
3.85
|
|
|
$
|
2.41
|
|
|
$
|
2.39
|
|
|
$
|
3.33
|
|
|
$
|
(4.46
|
)
|
|
(Loss) income from discontinued operations, net of taxes
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(0.01
|
)
|
|
0.10
|
|
|||||
|
Net income (loss) attributable to Leidos common stockholders
|
|
$
|
3.85
|
|
|
$
|
2.41
|
|
|
$
|
2.39
|
|
|
$
|
3.32
|
|
|
$
|
(4.36
|
)
|
|
Diluted:
|
|
|
|
|
|
|
|
|
|
|
||||||||||
|
Income (loss) from continuing operations attributable to Leidos common stockholders
|
|
$
|
3.80
|
|
|
$
|
2.38
|
|
|
$
|
2.35
|
|
|
$
|
3.28
|
|
|
$
|
(4.46
|
)
|
|
(Loss) income from discontinued operations, net of taxes
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(0.01
|
)
|
|
0.10
|
|
|||||
|
Net income (loss) attributable to Leidos common stockholders
|
|
$
|
3.80
|
|
|
$
|
2.38
|
|
|
$
|
2.35
|
|
|
$
|
3.27
|
|
|
$
|
(4.36
|
)
|
|
Cash dividend per common share
|
|
$
|
1.28
|
|
|
$
|
1.28
|
|
|
$
|
14.92
|
|
|
$
|
1.28
|
|
|
$
|
1.28
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||
|
|
|
December 28,
2018 |
|
December 29,
2017 |
|
December 30,
2016 |
|
January 1,
2016 |
|
January 30,
2015 |
||||||||||
|
|
|
(in millions)
|
||||||||||||||||||
|
Consolidated Balance Sheet Data:
|
|
|
|
|
|
|
|
|
|
|
||||||||||
|
Total assets
|
|
$
|
8,770
|
|
|
$
|
8,990
|
|
|
$
|
9,132
|
|
|
$
|
3,370
|
|
|
$
|
3,281
|
|
|
Long-term debt, including current portion
|
|
3,124
|
|
|
3,111
|
|
|
3,287
|
|
|
1,081
|
|
|
1,158
|
|
|||||
|
Other long-term liabilities
(7)
|
|
178
|
|
|
129
|
|
|
204
|
|
|
149
|
|
|
147
|
|
|||||
|
(1)
|
References to financial data are to the Company's continuing operations, unless otherwise noted.
|
|
(2)
|
Fiscal 2018 reflects the effects from our December 30, 2017 adoption of ASC 606. Fiscal 2018 also includes acquisition, integration and restructuring costs of
$37 million
and a tangible asset impairment charge of
$7 million
. For further information, see "
Note 6—Acquisitions
," "
Note 8—Restructuring Expenses
" and "
Note 12—Property, Plant and Equipment
" of the notes to the consolidated financial statements contained within this Annual Report on Form 10-K.
|
|
(3)
|
Fiscal 2017 includes acquisition, integration and restructuring costs of
$139 million
. For further information, see "
Note 6—Acquisitions
" and "
Note 8—Restructuring Expenses
" of the notes to the consolidated financial statements contained within this Annual Report on Form 10-K.
|
|
(4)
|
Fiscal 2016 includes acquisition, integration and restructuring costs of
$104 million
. For further detail regarding the acquisition of the IS&GS Business, see "
Note 6—Acquisitions
" and "
Note 8—Restructuring Expenses
" of the notes to the consolidated financial statements contained within this Annual Report on Form 10-K.
|
|
(5)
|
Reflects the 11-month period of January 31, 2015, through January 1, 2016, as a result of the change in our fiscal year end. The 11-month period ended January 1, 2016, results include a gain on a real estate sale of
$82 million
, tangible asset impairment charges of $
29 million
, intangible asset impairment charges of $
4 million
and bad debt expense of
$8 million
.
|
|
(6)
|
Fiscal 2015 results include goodwill impairment charges of
$486 million
, intangible asset impairment charges of
$41 million
and a tangible asset impairment charge of
$40 million
.
|
|
(7)
|
Beginning in fiscal 2016, the Company has separately disclosed "Deferred tax liabilities," which was previously aggregated within "Other long-term liabilities" within the consolidated balance sheets. Deferred tax liabilities for the 11-month period ended January 1, 2016 and fiscal 2015 were
$34 million
and
$21 million
, respectively.
|
|
•
|
achieving internal, or non-acquisition related, annual revenue growth through internal collaboration and better leveraging of key differentiators across our company and the deployment of resources and investments into higher growth markets;
|
|
•
|
increasing headcount and internal direct labor content on our contract portfolio;
|
|
•
|
continued improvement in our back office infrastructure and related business processes for greater effectiveness and efficiency across all business functions; and
|
|
•
|
disciplined deployment of our cash resources and use of our capital structure to enhance shareholder value while retaining an appropriate amount of financial leverage, through internal growth initiatives, stock repurchases, dividends, strategic acquisitions, debt level management and other uses to achieve our goals.
|
|
|
|
Year Ended
|
|
2018 to 2017
|
|
2017 to 2016
|
||||||||||||||||||||
|
|
|
December 28,
2018 |
|
December 29,
2017 |
|
December 30,
2016 |
|
Dollar change
|
|
Percent
change |
|
Dollar change
|
|
Percent
change |
||||||||||||
|
|
|
(dollars in millions)
|
||||||||||||||||||||||||
|
Revenues
|
|
$
|
10,194
|
|
|
$
|
10,170
|
|
|
$
|
7,043
|
|
|
$
|
24
|
|
|
—
|
%
|
|
$
|
3,127
|
|
|
44
|
%
|
|
Cost of revenues
(1)
|
|
8,690
|
|
|
8,738
|
|
|
6,103
|
|
|
(48
|
)
|
|
(1
|
)%
|
|
2,635
|
|
|
43
|
%
|
|||||
|
Selling, general and administrative expenses:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
|
General and administrative
(1)
|
|
547
|
|
|
573
|
|
|
289
|
|
|
(26
|
)
|
|
(5
|
)%
|
|
284
|
|
|
98
|
%
|
|||||
|
Bid and proposal
|
|
136
|
|
|
122
|
|
|
89
|
|
|
14
|
|
|
11
|
%
|
|
33
|
|
|
37
|
%
|
|||||
|
Internal research and development
|
|
46
|
|
|
42
|
|
|
44
|
|
|
4
|
|
|
10
|
%
|
|
(2
|
)
|
|
(5
|
)%
|
|||||
|
Bad debt expense
|
|
—
|
|
|
10
|
|
|
3
|
|
|
(10
|
)
|
|
(100
|
)%
|
|
7
|
|
|
NM
|
|
|||||
|
Acquisition, integration and restructuring costs
|
|
37
|
|
|
139
|
|
|
104
|
|
|
(102
|
)
|
|
(73
|
)%
|
|
35
|
|
|
34
|
%
|
|||||
|
Asset impairment charges
|
|
7
|
|
|
—
|
|
|
4
|
|
|
7
|
|
|
100
|
%
|
|
(4
|
)
|
|
(100
|
)%
|
|||||
|
Equity earnings of non-consolidated subsidiaries
|
|
(18
|
)
|
|
(13
|
)
|
|
(10
|
)
|
|
(5
|
)
|
|
38
|
%
|
|
(3
|
)
|
|
30
|
%
|
|||||
|
Operating income
|
|
749
|
|
|
559
|
|
|
417
|
|
|
190
|
|
|
34
|
%
|
|
142
|
|
|
34
|
%
|
|||||
|
Non-operating expense, net
|
|
(139
|
)
|
|
(166
|
)
|
|
(99
|
)
|
|
27
|
|
|
(16
|
)%
|
|
(67
|
)
|
|
68
|
%
|
|||||
|
Income before income taxes
|
|
610
|
|
|
393
|
|
|
318
|
|
|
217
|
|
|
55
|
%
|
|
75
|
|
|
24
|
%
|
|||||
|
Income tax expense
|
|
(28
|
)
|
|
(29
|
)
|
|
(72
|
)
|
|
1
|
|
|
(3
|
)%
|
|
43
|
|
|
(60
|
)%
|
|||||
|
Net income
|
|
582
|
|
|
364
|
|
|
246
|
|
|
218
|
|
|
60
|
%
|
|
118
|
|
|
48
|
%
|
|||||
|
Less: net income (loss) attributable to non-controlling interest
|
|
1
|
|
|
(2
|
)
|
|
2
|
|
|
3
|
|
|
150
|
%
|
|
(4
|
)
|
|
(200
|
)%
|
|||||
|
Net income attributable to Leidos Holdings, Inc.
|
|
$
|
581
|
|
|
$
|
366
|
|
|
$
|
244
|
|
|
$
|
215
|
|
|
59
|
%
|
|
$
|
122
|
|
|
50
|
%
|
|
Operating income margin
|
|
7.3
|
%
|
|
5.5
|
%
|
|
5.9
|
%
|
|
|
|
|
|
|
|
|
|||||||||
|
(1)
|
Effective the beginning of fiscal 2018, the Company established a new U.S. government Cost Accounting Standards structure and revised its disclosure statements accordingly to reflect the related cost accounting practice changes. Consequently,
$185 million
and
$88 million
was reclassified from "Cost of revenues" to "Selling, general and administrative expenses" on the consolidated statements of income for fiscal 2017 and 2016, respectively. For more information, see "
Note 1—Nature of Operations and Basis of Presentation
" of the notes to the consolidated financial statements contained within this Annual Report on Form 10-K.
|
|
|
|
Year Ended
|
|
2018 to 2017
|
|
2017 to 2016
|
||||||||||||||||||||
|
Defense Solutions
|
|
December 28,
2018 |
|
December 29,
2017 |
|
December 30,
2016 |
|
Dollar change
|
|
Percent
change |
|
Dollar change
|
|
Percent
change |
||||||||||||
|
|
|
(dollars in millions)
|
||||||||||||||||||||||||
|
Revenues
|
|
$
|
4,948
|
|
|
$
|
4,959
|
|
|
$
|
3,843
|
|
|
$
|
(11
|
)
|
|
—
|
%
|
|
$
|
1,116
|
|
|
29
|
%
|
|
Operating income
|
|
347
|
|
|
307
|
|
|
312
|
|
|
40
|
|
|
13
|
%
|
|
(5
|
)
|
|
(2
|
)%
|
|||||
|
Operating income margin
|
|
7.0
|
%
|
|
6.2
|
%
|
|
8.1
|
%
|
|
|
|
|
|
|
|
|
|||||||||
|
|
|
Year Ended
|
|
2018 to 2017
|
|
2017 to 2016
|
||||||||||||||||||||
|
Civil
|
|
December 28,
2018 |
|
December 29,
2017 |
|
December 30,
2016 |
|
Dollar change
|
|
Percent change
|
|
Dollar change
|
|
Percent change
|
||||||||||||
|
|
|
(dollars in millions)
|
||||||||||||||||||||||||
|
Revenues
|
|
$
|
3,429
|
|
|
$
|
3,409
|
|
|
$
|
2,082
|
|
|
$
|
20
|
|
|
1
|
%
|
|
$
|
1,327
|
|
|
64
|
%
|
|
Operating income
|
|
290
|
|
|
226
|
|
|
146
|
|
|
64
|
|
|
28
|
%
|
|
80
|
|
|
55
|
%
|
|||||
|
Operating income margin
|
|
8.5
|
%
|
|
6.6
|
%
|
|
7.0
|
%
|
|
|
|
|
|
|
|
|
|||||||||
|
|
|
Year Ended
|
|
2018 to 2017
|
|
2017 to 2016
|
||||||||||||||||||||
|
Health
|
|
December 28,
2018 |
|
December 29,
2017 |
|
December 30,
2016 |
|
Dollar change
|
|
Percent
change |
|
Dollar change
|
|
Percent
change |
||||||||||||
|
|
|
(dollars in millions)
|
||||||||||||||||||||||||
|
Revenues
|
|
$
|
1,817
|
|
|
$
|
1,802
|
|
|
$
|
1,117
|
|
|
$
|
15
|
|
|
1
|
%
|
|
$
|
685
|
|
|
61
|
%
|
|
Operating income
|
|
230
|
|
|
228
|
|
|
110
|
|
|
2
|
|
|
1
|
%
|
|
118
|
|
|
107
|
%
|
|||||
|
Operating income margin
|
|
12.7
|
%
|
|
12.7
|
%
|
|
9.8
|
%
|
|
|
|
|
|
|
|
|
|||||||||
|
|
|
Year Ended
|
|
2018 to 2017
|
|
2017 to 2016
|
||||||||||||||||||||
|
Corporate
|
|
December 28,
2018 |
|
December 29,
2017 |
|
December 30,
2016 |
|
Dollar change
|
|
Percent
change |
|
Dollar change
|
|
Percent
change |
||||||||||||
|
|
|
(dollars in millions)
|
||||||||||||||||||||||||
|
Revenues
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
1
|
|
|
$
|
—
|
|
|
—
|
%
|
|
$
|
(1
|
)
|
|
(100
|
)%
|
|
Operating loss
|
|
(118
|
)
|
|
(202
|
)
|
|
(151
|
)
|
|
84
|
|
|
(42
|
)%
|
|
(51
|
)
|
|
34
|
%
|
|||||
|
•
|
Funded Backlog.
Funded backlog for contracts with the U.S. government represents the value on contracts for which funding is appropriated less revenues previously recognized on these contracts. Funded backlog for contracts with non-U.S. government entities and commercial customers represents the estimated value on contracts, which may cover multiple future years, under which we are obligated to perform, less revenues previously recognized on the contracts.
|
|
•
|
Negotiated Unfunded Backlog.
Negotiated unfunded backlog represents estimated amounts of revenue to be earned in the future from contracts for which funding has not been appropriated and unexercised priced contract options. Negotiated unfunded backlog does not include future potential task orders expected to be awarded under IDIQ, GSA Schedule or other master agreement contract vehicles, with the exception of certain IDIQ contracts where task orders are not competitively awarded and separately priced but instead are used as a funding mechanism, and where there is a basis for estimating future revenues and funding on future task orders is anticipated.
|
|
|
|
December 28,
2018 |
|
December 29,
2017 |
||||
|
|
|
(in millions)
|
||||||
|
Defense Solutions:
|
|
|
|
|
||||
|
Funded backlog
|
|
$
|
2,811
|
|
|
$
|
2,384
|
|
|
Negotiated unfunded backlog
|
|
6,891
|
|
|
5,285
|
|
||
|
Total Defense Solutions backlog
|
|
$
|
9,702
|
|
|
$
|
7,669
|
|
|
Civil:
|
|
|
|
|
||||
|
Funded backlog
|
|
$
|
2,314
|
|
|
$
|
2,064
|
|
|
Negotiated unfunded backlog
|
|
5,079
|
|
|
5,321
|
|
||
|
Total Civil backlog
|
|
$
|
7,393
|
|
|
$
|
7,385
|
|
|
Health:
|
|
|
|
|
||||
|
Funded backlog
|
|
$
|
1,254
|
|
|
$
|
595
|
|
|
Negotiated unfunded backlog
|
|
2,483
|
|
|
1,827
|
|
||
|
Total Health backlog
|
|
$
|
3,737
|
|
|
$
|
2,422
|
|
|
Total:
|
|
|
|
|
||||
|
Funded backlog
|
|
$
|
6,379
|
|
|
$
|
5,043
|
|
|
Negotiated unfunded backlog
|
|
14,453
|
|
|
12,433
|
|
||
|
Total backlog
|
|
$
|
20,832
|
|
|
$
|
17,476
|
|
|
|
|
Year Ended
|
|||||||
|
|
|
December 28,
2018 |
|
December 29,
2017 |
|
December 30,
2016 |
|||
|
Cost-reimbursement and fixed-price-incentive-fee
|
|
54
|
%
|
|
56
|
%
|
|
51
|
%
|
|
Firm-fixed-price
|
|
31
|
|
|
28
|
|
|
30
|
|
|
Time-and-materials and fixed-price-level-of-effort
|
|
15
|
|
|
16
|
|
|
19
|
|
|
Total
|
|
100
|
%
|
|
100
|
%
|
|
100
|
%
|
|
|
|
Year Ended
|
||||||||||
|
|
|
December 28,
2018 |
|
December 29,
2017 |
|
December 30,
2016 |
||||||
|
|
|
(in millions)
|
||||||||||
|
Net cash provided by operating activities of continuing operations
|
|
$
|
768
|
|
|
$
|
526
|
|
|
$
|
449
|
|
|
Net cash (used in) provided by investing activities of continuing operations
|
|
(114
|
)
|
|
(71
|
)
|
|
26
|
|
|||
|
Net cash used in financing activities of continuing operations
|
|
(707
|
)
|
|
(429
|
)
|
|
(751
|
)
|
|||
|
Net decrease in cash, cash equivalents and restricted cash from discontinued operations
|
|
—
|
|
|
—
|
|
|
(1
|
)
|
|||
|
Net (decrease) increase in cash, cash equivalents and restricted cash
|
|
$
|
(53
|
)
|
|
$
|
26
|
|
|
$
|
(277
|
)
|
|
|
|
Total
|
|
2019
|
|
2020
|
|
2021
|
|
2022
|
|
2023
|
|
2024 and thereafter
|
||||||||||||||
|
|
|
(in millions)
|
||||||||||||||||||||||||||
|
Contractual obligations
(1)
:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||
|
Long-term debt (including current portion)
(2)
|
|
$
|
4,318
|
|
|
$
|
237
|
|
|
$
|
634
|
|
|
$
|
299
|
|
|
$
|
212
|
|
|
$
|
717
|
|
|
$
|
2,219
|
|
|
Operating lease obligations
|
|
713
|
|
|
144
|
|
|
114
|
|
|
83
|
|
|
71
|
|
|
55
|
|
|
246
|
|
|||||||
|
Capital lease obligations
|
|
3
|
|
|
3
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|||||||
|
Other long-term liabilities
(3)
|
|
91
|
|
|
7
|
|
|
10
|
|
|
7
|
|
|
7
|
|
|
7
|
|
|
53
|
|
|||||||
|
Total contractual obligations
|
|
$
|
5,125
|
|
|
$
|
391
|
|
|
$
|
758
|
|
|
$
|
389
|
|
|
$
|
290
|
|
|
$
|
779
|
|
|
$
|
2,518
|
|
|
(1)
|
We have excluded purchase orders for services or products to be delivered pursuant to U.S. government contracts for which we are entitled to full recourse under normal contract termination clauses.
|
|
(2)
|
Includes total interest payments on our outstanding debt. Interest payments represent
$161 million
,
$125 million
,
$118 million
,
$110 million
and
$98 million
of the balance for fiscal
2019
,
2020
,
2021
,
2022
and
2023
, respectively, and
$542 million
for fiscal
2024 and thereafter
. The total interest payments on our outstanding term loan debt are calculated based on the stated variable rates of the notes as of
December 28, 2018
. The total interest payments on our outstanding senior fixed rate secured and unsecured notes are calculated based on the stated fixed rates and do not reflect the variable interest component due to the interest rate swap agreements.
|
|
(3)
|
Other long-term liabilities were allocated by fiscal year as follows: liabilities under deferred compensation arrangements are based upon the average annual payments in prior years upon termination of employment by participants and other liabilities are based on the fiscal year that the liabilities are expected to be realized. The table above does not include income tax liabilities for uncertain tax positions of
$3 million
and
$4 million
of other tax liabilities, as we are not able to reasonably estimate the timing of payments in individual years due to uncertainties in the timing of audit outcomes and when settlements will become due. There is no obligation included for our foreign defined benefit pension plan, as the plan is overfunded as of
December 28, 2018
. For a discussion of potential changes in these pension obligations, see "
Note 21—Retirement Plans
" of the notes to the consolidated financial statements contained within this Annual Report on Form 10-K.
|
|
•
|
Revenue Recognition
|
|
•
|
Changes in Estimates on Contracts
|
|
•
|
Goodwill Impairment
|
|
•
|
Intangible Assets Impairment
|
|
•
|
Income Taxes
|
|
|
|
Year Ended
|
||||||||||
|
|
|
December 28,
2018 |
|
December 29,
2017 |
|
December 30,
2016 |
||||||
|
|
|
(in millions, except for per share amounts)
|
||||||||||
|
Net favorable impact to income before income taxes
|
|
$
|
105
|
|
|
$
|
103
|
|
|
$
|
37
|
|
|
Impact on diluted EPS attributable to Leidos common stockholders
|
|
$
|
0.52
|
|
|
$
|
0.41
|
|
|
$
|
0.22
|
|
|
|
|
Page
|
|
CONSOLIDATED FINANCIAL STATEMENTS
|
|
|
|
|
|
|
|
|
||
|
|
|
|
|
|
||
|
|
|
|
|
|
||
|
|
|
|
|
|
||
|
|
|
|
|
|
||
|
|
|
|
|
|
||
|
|
|
|
|
|
||
|
|
|
December 28,
2018 |
|
December 29,
2017 |
||||
|
|
|
(in millions)
|
||||||
|
ASSETS
|
|
|
|
|
||||
|
Cash and cash equivalents
|
|
$
|
327
|
|
|
$
|
390
|
|
|
Receivables, net
|
|
1,877
|
|
|
1,831
|
|
||
|
Other current assets
|
|
543
|
|
|
453
|
|
||
|
Assets held for sale
|
|
92
|
|
|
—
|
|
||
|
Total current assets
|
|
2,839
|
|
|
2,674
|
|
||
|
Property, plant and equipment, net
|
|
237
|
|
|
232
|
|
||
|
Intangible assets, net
|
|
652
|
|
|
856
|
|
||
|
Goodwill
|
|
4,860
|
|
|
4,974
|
|
||
|
Other assets
|
|
182
|
|
|
254
|
|
||
|
|
|
$
|
8,770
|
|
|
$
|
8,990
|
|
|
LIABILITIES AND EQUITY
|
|
|
|
|
||||
|
Accounts payable and accrued liabilities
|
|
$
|
1,476
|
|
|
$
|
1,639
|
|
|
Accrued payroll and employee benefits
|
|
473
|
|
|
487
|
|
||
|
Dividends payable
|
|
12
|
|
|
17
|
|
||
|
Income taxes payable
|
|
3
|
|
|
4
|
|
||
|
Long-term debt, current portion
|
|
72
|
|
|
55
|
|
||
|
Liabilities held for sale
|
|
23
|
|
|
—
|
|
||
|
Total current liabilities
|
|
2,059
|
|
|
2,202
|
|
||
|
Long-term debt, net of current portion
|
|
3,052
|
|
|
3,056
|
|
||
|
Deferred tax liabilities
|
|
170
|
|
|
220
|
|
||
|
Other long-term liabilities
|
|
178
|
|
|
129
|
|
||
|
Commitments and contingencies (Notes 22, 25 and 26)
|
|
|
|
|
||||
|
Stockholders’ equity:
|
|
|
|
|
||||
|
Preferred stock, $.0001 par value,10 million shares authorized and no shares issued and outstanding at December 28, 2018, and December 29, 2017
|
|
—
|
|
|
—
|
|
||
|
Common stock, $.0001 par value, 500 million shares authorized, 146 million and 151 million shares issued and outstanding at December 28, 2018, and December 29, 2017, respectively
|
|
—
|
|
|
—
|
|
||
|
Additional paid-in capital
|
|
2,966
|
|
|
3,344
|
|
||
|
Accumulated earnings (deficit)
|
|
372
|
|
|
(7
|
)
|
||
|
Accumulated other comprehensive (loss) income
|
|
(30
|
)
|
|
33
|
|
||
|
Total Leidos stockholders’ equity
|
|
3,308
|
|
|
3,370
|
|
||
|
Non-controlling interest
|
|
3
|
|
|
13
|
|
||
|
Total equity
|
|
3,311
|
|
|
3,383
|
|
||
|
|
|
$
|
8,770
|
|
|
$
|
8,990
|
|
|
|
|
Year Ended
|
||||||||||
|
|
|
December 28,
2018 |
|
December 29,
2017 |
|
December 30,
2016 |
||||||
|
|
|
(in millions, except per share amounts)
|
||||||||||
|
Revenues
|
|
$
|
10,194
|
|
|
$
|
10,170
|
|
|
$
|
7,043
|
|
|
Cost of revenues
|
|
8,690
|
|
|
8,738
|
|
|
6,103
|
|
|||
|
Selling, general and administrative expenses
|
|
729
|
|
|
737
|
|
|
422
|
|
|||
|
Bad debt expense
|
|
—
|
|
|
10
|
|
|
3
|
|
|||
|
Acquisition, integration and restructuring costs
|
|
37
|
|
|
139
|
|
|
104
|
|
|||
|
Asset impairment charges
|
|
7
|
|
|
—
|
|
|
4
|
|
|||
|
Equity earnings of non-consolidated subsidiaries
|
|
(18
|
)
|
|
(13
|
)
|
|
(10
|
)
|
|||
|
Operating income
|
|
749
|
|
|
559
|
|
|
417
|
|
|||
|
Non-operating expense:
|
|
|
|
|
|
|
||||||
|
Interest expense, net
|
|
(138
|
)
|
|
(140
|
)
|
|
(86
|
)
|
|||
|
Other expense, net
|
|
(1
|
)
|
|
(26
|
)
|
|
(13
|
)
|
|||
|
Income before income taxes
|
|
610
|
|
|
393
|
|
|
318
|
|
|||
|
Income tax expense
|
|
(28
|
)
|
|
(29
|
)
|
|
(72
|
)
|
|||
|
Net income
|
|
582
|
|
|
364
|
|
|
246
|
|
|||
|
Less: net income (loss) attributable to non-controlling interest
|
|
1
|
|
|
(2
|
)
|
|
2
|
|
|||
|
Net income attributable to Leidos common stockholders
|
|
$
|
581
|
|
|
$
|
366
|
|
|
$
|
244
|
|
|
|
|
|
|
|
|
|
||||||
|
Earnings per share:
|
|
|
|
|
|
|
||||||
|
Basic
|
|
$
|
3.85
|
|
|
$
|
2.41
|
|
|
$
|
2.39
|
|
|
Diluted
|
|
3.80
|
|
|
2.38
|
|
|
2.35
|
|
|||
|
|
|
Year Ended
|
||||||||||
|
|
|
December 28,
2018 |
|
December 29,
2017 |
|
December 30,
2016 |
||||||
|
|
|
(in millions)
|
||||||||||
|
Net income
|
|
$
|
582
|
|
|
$
|
364
|
|
|
$
|
246
|
|
|
Foreign currency translation adjustments
|
|
(61
|
)
|
|
24
|
|
|
(7
|
)
|
|||
|
Unrecognized (loss) gain on derivative instruments
|
|
(10
|
)
|
|
4
|
|
|
14
|
|
|||
|
Pension adjustments
|
|
(1
|
)
|
|
9
|
|
|
(3
|
)
|
|||
|
Total other comprehensive (loss) income, net of taxes
|
|
(72
|
)
|
|
37
|
|
|
4
|
|
|||
|
Comprehensive income
|
|
510
|
|
|
401
|
|
|
250
|
|
|||
|
Less: comprehensive income (loss) attributable to non-controlling interest
|
|
1
|
|
|
(2
|
)
|
|
2
|
|
|||
|
Comprehensive income attributable to Leidos common stockholders
|
|
$
|
509
|
|
|
$
|
403
|
|
|
$
|
248
|
|
|
|
|
Shares of common stock
|
|
Additional
paid-in capital |
|
Accumulated earnings (deficit)
|
|
Accumulated
other comprehensive (loss) income |
|
Leidos Holdings, Inc. stockholders' equity
|
|
Non-controlling interest
|
|
Total
|
|||||||||||||
|
|
|
|
|||||||||||||||||||||||||
|
|
|
(in millions, except for per share amounts)
|
|||||||||||||||||||||||||
|
Balance at January 1, 2016
|
|
72
|
|
|
$
|
1,353
|
|
|
$
|
(277
|
)
|
|
$
|
(8
|
)
|
|
$
|
1,068
|
|
|
$
|
—
|
|
|
$
|
1,068
|
|
|
Net income
|
|
—
|
|
|
—
|
|
|
244
|
|
|
—
|
|
|
244
|
|
|
2
|
|
|
246
|
|
||||||
|
Other comprehensive income, net of tax
es
|
|
—
|
|
|
—
|
|
|
—
|
|
|
4
|
|
|
4
|
|
|
—
|
|
|
4
|
|
||||||
|
Issuances of stock (less forfeitures)
|
|
1
|
|
|
36
|
|
|
—
|
|
|
—
|
|
|
36
|
|
|
—
|
|
|
36
|
|
||||||
|
Repurchases of stock and other
|
|
—
|
|
|
(24
|
)
|
|
—
|
|
|
—
|
|
|
(24
|
)
|
|
—
|
|
|
(24
|
)
|
||||||
|
Dividends of $1.28 per share
|
|
—
|
|
|
—
|
|
|
(144
|
)
|
|
—
|
|
|
(144
|
)
|
|
—
|
|
|
(144
|
)
|
||||||
|
Special cash dividend of $13.64 per share
|
|
—
|
|
|
(1,022
|
)
|
|
—
|
|
|
—
|
|
|
(1,022
|
)
|
|
—
|
|
|
(1,022
|
)
|
||||||
|
Stock-based compensation
|
|
—
|
|
|
35
|
|
|
—
|
|
|
—
|
|
|
35
|
|
|
—
|
|
|
35
|
|
||||||
|
Stock issued for the IS&GS Business acquisition
|
|
77
|
|
|
2,938
|
|
|
—
|
|
|
—
|
|
|
2,938
|
|
|
—
|
|
|
2,938
|
|
||||||
|
Equity interest acquired
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
10
|
|
|
10
|
|
||||||
|
Balance at December 30, 2016
|
|
150
|
|
|
3,316
|
|
|
(177
|
)
|
|
(4
|
)
|
|
3,135
|
|
|
12
|
|
|
3,147
|
|
||||||
|
Net income (loss)
|
|
—
|
|
|
—
|
|
|
366
|
|
|
—
|
|
|
366
|
|
|
(2
|
)
|
|
364
|
|
||||||
|
Other comprehensive income, net of taxes
|
|
—
|
|
|
—
|
|
|
—
|
|
|
37
|
|
|
37
|
|
|
—
|
|
|
37
|
|
||||||
|
Issuances of stock (less forfeitures)
|
|
1
|
|
|
16
|
|
|
—
|
|
|
—
|
|
|
16
|
|
|
—
|
|
|
16
|
|
||||||
|
Repurchases of stock and other
|
|
—
|
|
|
(31
|
)
|
|
—
|
|
|
—
|
|
|
(31
|
)
|
|
—
|
|
|
(31
|
)
|
||||||
|
Dividends of $1.28 per share
|
|
—
|
|
|
—
|
|
|
(196
|
)
|
|
—
|
|
|
(196
|
)
|
|
—
|
|
|
(196
|
)
|
||||||
|
Stock-based compensation
|
|
—
|
|
|
43
|
|
|
—
|
|
|
—
|
|
|
43
|
|
|
—
|
|
|
43
|
|
||||||
|
Adjustment to original purchase price allocation
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
3
|
|
|
3
|
|
||||||
|
Balance at December 29, 2017
|
|
151
|
|
|
3,344
|
|
|
(7
|
)
|
|
33
|
|
|
3,370
|
|
|
13
|
|
|
3,383
|
|
||||||
|
Cumulative adjustments related to ASU adoptions
|
|
—
|
|
|
—
|
|
|
(8
|
)
|
|
9
|
|
|
1
|
|
|
—
|
|
|
1
|
|
||||||
|
Balance at December 30, 2017
|
|
151
|
|
|
3,344
|
|
|
(15
|
)
|
|
42
|
|
|
3,371
|
|
|
13
|
|
|
3,384
|
|
||||||
|
Net income
|
|
—
|
|
|
—
|
|
|
581
|
|
|
—
|
|
|
581
|
|
|
1
|
|
|
582
|
|
||||||
|
Other comprehensive loss, net of taxes
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(72
|
)
|
|
(72
|
)
|
|
—
|
|
|
(72
|
)
|
||||||
|
Issuances of stock (less forfeitures)
|
|
1
|
|
|
17
|
|
|
—
|
|
|
—
|
|
|
17
|
|
|
—
|
|
|
17
|
|
||||||
|
Repurchases of stock and other
|
|
(6
|
)
|
|
(438
|
)
|
|
—
|
|
|
—
|
|
|
(438
|
)
|
|
—
|
|
|
(438
|
)
|
||||||
|
Dividends of $1.28 per share
|
|
—
|
|
|
—
|
|
|
(194
|
)
|
|
—
|
|
|
(194
|
)
|
|
—
|
|
|
(194
|
)
|
||||||
|
Stock-based compensation
|
|
—
|
|
|
44
|
|
|
—
|
|
|
—
|
|
|
44
|
|
|
—
|
|
|
44
|
|
||||||
|
Purchase of a non-controlling interest
|
|
—
|
|
|
(1
|
)
|
|
—
|
|
|
—
|
|
|
(1
|
)
|
|
(10
|
)
|
|
(11
|
)
|
||||||
|
Other
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(1
|
)
|
|
(1
|
)
|
||||||
|
Balance at December 28, 2018
|
|
146
|
|
|
$
|
2,966
|
|
|
$
|
372
|
|
|
$
|
(30
|
)
|
|
$
|
3,308
|
|
|
$
|
3
|
|
|
$
|
3,311
|
|
|
|
|
Year Ended
|
||||||||||
|
|
|
December 28,
2018 |
|
December 29,
2017 |
|
December 30,
2016 |
||||||
|
|
|
(in millions)
|
||||||||||
|
Cash flows from operations:
|
|
|
|
|
|
|
||||||
|
Net income
|
|
$
|
582
|
|
|
$
|
364
|
|
|
$
|
246
|
|
|
Adjustments to reconcile net income to net cash provided by continuing operations:
|
|
|
|
|
|
|
||||||
|
Depreciation and amortization
|
|
257
|
|
|
336
|
|
|
122
|
|
|||
|
Amortization of equity method investments
|
|
10
|
|
|
14
|
|
|
—
|
|
|||
|
Stock-based compensation
|
|
44
|
|
|
43
|
|
|
35
|
|
|||
|
Asset impairment charges
|
|
7
|
|
|
—
|
|
|
4
|
|
|||
|
Non-cash interest expense
|
|
6
|
|
|
12
|
|
|
4
|
|
|||
|
Promissory note impairment
|
|
—
|
|
|
33
|
|
|
—
|
|
|||
|
Bad debt expense
|
|
—
|
|
|
10
|
|
|
3
|
|
|||
|
Other
|
|
2
|
|
|
9
|
|
|
(7
|
)
|
|||
|
Change in assets and liabilities, net of effects of acquisitions and dispositions:
|
|
|
|
|
|
|
||||||
|
Receivables
|
|
(58
|
)
|
|
(191
|
)
|
|
123
|
|
|||
|
Other current assets
|
|
(73
|
)
|
|
(76
|
)
|
|
(98
|
)
|
|||
|
Accounts payable and accrued liabilities
|
|
(46
|
)
|
|
152
|
|
|
(25
|
)
|
|||
|
Accrued payroll and employee benefits
|
|
(12
|
)
|
|
8
|
|
|
26
|
|
|||
|
Deferred income taxes and income taxes receivable/payable
|
|
(39
|
)
|
|
(151
|
)
|
|
36
|
|
|||
|
Other long-term assets/liabilities
|
|
88
|
|
|
(37
|
)
|
|
(20
|
)
|
|||
|
Net cash provided by operating activities of continuing operations
|
|
768
|
|
|
526
|
|
|
449
|
|
|||
|
Cash flows from investing activities:
|
|
|
|
|
|
|
||||||
|
Payments for property, plant and equipment
|
|
(73
|
)
|
|
(81
|
)
|
|
(29
|
)
|
|||
|
Collections on promissory note
|
|
40
|
|
|
2
|
|
|
4
|
|
|||
|
Acquisitions of businesses
|
|
(81
|
)
|
|
—
|
|
|
25
|
|
|||
|
Net proceeds from sale of assets
|
|
—
|
|
|
8
|
|
|
3
|
|
|||
|
Proceeds from disposition of business
|
|
—
|
|
|
—
|
|
|
23
|
|
|||
|
Net cash (used in) provided by investing activities of continuing operations
|
|
(114
|
)
|
|
(71
|
)
|
|
26
|
|
|||
|
|
|
Year Ended
|
||||||||||
|
|
|
December 28,
2018 |
|
December 29,
2017 |
|
December 30,
2016 |
||||||
|
|
|
(in millions)
|
||||||||||
|
Cash flows from financing activities:
|
|
|
|
|
|
|
||||||
|
Payments of long-term debt
|
|
(59
|
)
|
|
(209
|
)
|
|
(277
|
)
|
|||
|
Proceeds from debt issuance
|
|
—
|
|
|
—
|
|
|
690
|
|
|||
|
Payments for debt issuance and modification costs
|
|
(8
|
)
|
|
(4
|
)
|
|
(30
|
)
|
|||
|
Proceeds from issuances of stock
|
|
14
|
|
|
13
|
|
|
25
|
|
|||
|
Repurchases of stock and other
|
|
(438
|
)
|
|
(31
|
)
|
|
(24
|
)
|
|||
|
Special cash dividend payment
|
|
—
|
|
|
—
|
|
|
(993
|
)
|
|||
|
Dividend payments
|
|
(198
|
)
|
|
(198
|
)
|
|
(142
|
)
|
|||
|
Payment of tax indemnification liability
|
|
(23
|
)
|
|
—
|
|
|
—
|
|
|||
|
Proceeds from real estate financing transaction
|
|
14
|
|
|
—
|
|
|
—
|
|
|||
|
Payments for non-controlling interest acquired
|
|
(8
|
)
|
|
—
|
|
|
—
|
|
|||
|
Other
|
|
(1
|
)
|
|
—
|
|
|
—
|
|
|||
|
Net cash used in financing activities of continuing operations
|
|
(707
|
)
|
|
(429
|
)
|
|
(751
|
)
|
|||
|
Net (decrease) increase in cash, cash equivalents and restricted cash from continuing operations
|
|
(53
|
)
|
|
26
|
|
|
(276
|
)
|
|||
|
Cash flows from discontinued operations:
|
|
|
|
|
|
|
||||||
|
Net cash used in investing activities of discontinued operations
|
|
—
|
|
|
—
|
|
|
(1
|
)
|
|||
|
Net decrease in cash, cash equivalents and restricted cash from discontinued operations
|
|
—
|
|
|
—
|
|
|
(1
|
)
|
|||
|
Net (decrease) increase in cash, cash equivalents and restricted cash
|
|
(53
|
)
|
|
26
|
|
|
(277
|
)
|
|||
|
Cash, cash equivalents and restricted cash at beginning of year
|
|
422
|
|
|
396
|
|
|
673
|
|
|||
|
Cash, cash equivalents and restricted cash at end of year
|
|
$
|
369
|
|
|
$
|
422
|
|
|
$
|
396
|
|
|
|
|
Balance at December 29, 2017
|
|
Adjustments due to ASU 2014-09
|
|
Adjustments due to ASU 2017-12
|
|
Adjustments due to ASU 2018-02
|
|
Balance at December 30, 2017
|
||||||||||
|
|
|
(in millions)
|
||||||||||||||||||
|
Assets:
|
|
|
|
|
|
|
|
|
|
|
||||||||||
|
Receivables, net
|
|
$
|
1,831
|
|
|
$
|
4
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
1,835
|
|
|
Other current assets
|
|
453
|
|
|
(3
|
)
|
|
—
|
|
|
—
|
|
|
450
|
|
|||||
|
Equity:
|
|
|
|
|
|
|
|
|
|
|
||||||||||
|
Accumulated deficit
|
|
$
|
(7
|
)
|
|
$
|
1
|
|
|
$
|
(3
|
)
|
|
$
|
(6
|
)
|
|
$
|
(15
|
)
|
|
Accumulated other comprehensive income
|
|
33
|
|
|
—
|
|
|
3
|
|
|
6
|
|
|
42
|
|
|||||
|
|
|
Year Ended
|
||||||||||
|
|
|
December 28,
2018 |
|
December 29,
2017 |
|
December 30,
2016 |
||||||
|
|
|
(in millions, except for per share amounts)
|
||||||||||
|
Net favorable impact to income before income taxes
|
|
$
|
105
|
|
|
$
|
103
|
|
|
$
|
37
|
|
|
Impact on diluted EPS attributable to Leidos common stockholders
|
|
$
|
0.52
|
|
|
$
|
0.41
|
|
|
$
|
0.22
|
|
|
|
|
Estimated useful lives (in years)
|
|
Program and contract intangibles
|
|
6-11
|
|
Backlog
|
|
1
|
|
Customer relationships
|
|
8
|
|
Software and technology
|
|
4-15
|
|
|
|
Depreciation method
|
|
Estimated useful lives (in years)
|
|
Computers and other equipment
|
|
Straight-line or declining-balance
|
|
3-10
|
|
Buildings
|
|
Straight-line
|
|
Not to exceed 40
|
|
Building improvements and leasehold improvements
|
|
Straight-line
|
|
Shorter of useful life of asset or remaining lease term
|
|
Office furniture and fixtures
|
|
Straight-line or declining-balance
|
|
6-9
|
|
|
|
As Reported
(ASC 606)
|
|
As Adjusted
(ASC 605)
|
||||
|
|
|
(in millions)
|
||||||
|
Receivables, net
|
|
$
|
1,877
|
|
|
$
|
1,872
|
|
|
Other current assets
|
|
543
|
|
|
545
|
|
||
|
Accumulated earnings (deficit)
|
|
372
|
|
|
369
|
|
||
|
|
|
Year Ended December 28, 2018
|
||||||
|
|
|
As Reported
(ASC 606)
|
|
As Adjusted
(ASC 605) |
||||
|
|
|
(in millions)
|
||||||
|
Revenues
|
|
$
|
10,194
|
|
|
$
|
10,189
|
|
|
Cost of revenues
|
|
8,690
|
|
|
8,688
|
|
||
|
Operating income
|
|
749
|
|
|
746
|
|
||
|
|
|
Year Ended December 28, 2018
|
||||||||||||||
|
|
|
Defense Solutions
|
|
Civil
|
|
Health
|
|
Total
|
||||||||
|
|
|
(in millions)
|
||||||||||||||
|
DoD
|
|
$
|
4,318
|
|
|
$
|
128
|
|
|
$
|
386
|
|
|
$
|
4,832
|
|
|
Other government agencies
(1)
|
|
194
|
|
|
2,412
|
|
|
1,276
|
|
|
3,882
|
|
||||
|
Commercial and non-U.S. customers
|
|
436
|
|
|
889
|
|
|
155
|
|
|
1,480
|
|
||||
|
Total
|
|
$
|
4,948
|
|
|
$
|
3,429
|
|
|
$
|
1,817
|
|
|
$
|
10,194
|
|
|
|
|
Year Ended December 28, 2018
|
||||||||||||||
|
|
|
Defense Solutions
|
|
Civil
|
|
Health
|
|
Total
|
||||||||
|
|
|
(in millions)
|
||||||||||||||
|
Cost-reimbursement and fixed-price-incentive-fee
|
|
$
|
3,417
|
|
|
$
|
1,863
|
|
|
$
|
189
|
|
|
$
|
5,469
|
|
|
Firm-fixed-price
|
|
1,031
|
|
|
1,004
|
|
|
1,134
|
|
|
3,169
|
|
||||
|
Time-and-materials and fixed-price-level-of-effort
|
|
500
|
|
|
562
|
|
|
494
|
|
|
1,556
|
|
||||
|
Total
|
|
$
|
4,948
|
|
|
$
|
3,429
|
|
|
$
|
1,817
|
|
|
$
|
10,194
|
|
|
|
|
Year Ended December 28, 2018
|
||||||||||||||
|
|
|
Defense Solutions
|
|
Civil
|
|
Health
|
|
Total
|
||||||||
|
|
|
(in millions)
|
||||||||||||||
|
United States
|
|
$
|
4,572
|
|
|
$
|
2,876
|
|
|
$
|
1,817
|
|
|
$
|
9,265
|
|
|
International
|
|
376
|
|
|
553
|
|
|
—
|
|
|
929
|
|
||||
|
Total
|
|
$
|
4,948
|
|
|
$
|
3,429
|
|
|
$
|
1,817
|
|
|
$
|
10,194
|
|
|
|
|
Balance sheet line item
|
|
December 28,
2018 |
|
December 30, 2017
(1)
|
||||
|
|
|
|
|
(in millions)
|
||||||
|
Contract assets - current:
|
|
|
|
|
|
|
||||
|
Unbilled receivables
(2)
|
|
Receivables, net
|
|
$
|
818
|
|
|
$
|
844
|
|
|
|
|
|
|
|
|
|
||||
|
Contract liabilities - current:
|
|
|
|
|
|
|
||||
|
Deferred revenue
|
|
Accounts payable and accrued liabilities
|
|
$
|
276
|
|
|
$
|
293
|
|
|
|
|
|
|
|
|
|
||||
|
Contract liabilities - non-current:
|
|
|
|
|
|
|
||||
|
Deferred revenue
|
|
Other long-term liabilities
|
|
$
|
10
|
|
|
$
|
17
|
|
|
Value of common stock issued to Lockheed Martin stockholders
(1)
|
$
|
2,929
|
|
|
Equity consideration for replacement awards
(2)
|
9
|
|
|
|
Working capital adjustments
(3)
|
81
|
|
|
|
Purchase price
|
$
|
3,019
|
|
|
Cash
|
$
|
25
|
|
|
Receivables, net
|
938
|
|
|
|
Other current assets
|
73
|
|
|
|
Property, plant and equipment
|
87
|
|
|
|
Intangible assets
|
1,194
|
|
|
|
Other assets
|
58
|
|
|
|
Accounts payable and accrued liabilities
|
(733
|
)
|
|
|
Accrued payroll and employee benefits
|
(186
|
)
|
|
|
Long-term debt, current portion
|
(23
|
)
|
|
|
Deferred tax liabilities
|
(328
|
)
|
|
|
Long-term debt, net of current portion
|
(1,780
|
)
|
|
|
Other long-term liabilities
|
(45
|
)
|
|
|
Total identifiable net liabilities assumed
|
(720
|
)
|
|
|
Non-controlling interest
|
(13
|
)
|
|
|
Goodwill
|
3,752
|
|
|
|
Purchase price
|
$
|
3,019
|
|
|
|
|
Weighted average amortization period
|
|
Fair value
|
||
|
|
|
(in years)
|
|
(in millions)
|
||
|
Program and contract intangibles
(1)
|
|
9.7
|
|
$
|
1,011
|
|
|
Backlog
|
|
1.8
|
|
157
|
|
|
|
Software and technology
(1)
|
|
4.6
|
|
26
|
|
|
|
Total
|
|
8.6
|
|
$
|
1,194
|
|
|
|
|
Year Ended
|
||||||||||
|
|
|
December 28,
2018 |
|
December 29,
2017 |
|
December 30,
2016 |
||||||
|
|
|
(in millions)
|
||||||||||
|
Acquisition costs
|
|
$
|
—
|
|
|
$
|
25
|
|
|
$
|
44
|
|
|
Integration costs
|
|
29
|
|
|
77
|
|
|
46
|
|
|||
|
Total acquisition and integration costs
|
|
$
|
29
|
|
|
$
|
102
|
|
|
$
|
90
|
|
|
|
|
Year Ended
|
||
|
(unaudited)
|
|
December 30,
2016 |
||
|
|
|
(in millions, except for per share amounts)
|
||
|
Revenues
|
|
$
|
10,443
|
|
|
Net income
|
|
340
|
|
|
|
Net income attributable to Leidos common stockholders
|
|
335
|
|
|
|
Earnings per share:
|
|
|
||
|
Basic
|
|
$
|
2.23
|
|
|
Diluted
|
|
2.20
|
|
|
|
|
|
December 28,
2018 |
||
|
|
|
(in millions)
|
||
|
Receivables, net
|
|
$
|
16
|
|
|
Other current assets
|
|
5
|
|
|
|
Property, plant and equipment, net
|
|
3
|
|
|
|
Intangible assets, net
|
|
5
|
|
|
|
Goodwill
|
|
57
|
|
|
|
Deferred tax assets
|
|
6
|
|
|
|
Total assets held for sale
|
|
$
|
92
|
|
|
|
|
|
||
|
Accounts payable and accrued liabilities
|
|
$
|
16
|
|
|
Accrued payroll and employee benefits
|
|
4
|
|
|
|
Other long-term liabilities
|
|
3
|
|
|
|
Total liabilities held for sale
|
|
$
|
23
|
|
|
|
|
Year Ended
|
||||||||||
|
|
|
December 28,
2018 |
|
December 29,
2017 |
|
December 30,
2016 |
||||||
|
|
|
(in millions)
|
||||||||||
|
Severance costs
|
|
$
|
2
|
|
|
$
|
18
|
|
|
$
|
10
|
|
|
Lease termination expenses
|
|
6
|
|
|
19
|
|
|
2
|
|
|||
|
Restructuring expenses related to the IS&GS Business
|
|
$
|
8
|
|
|
$
|
37
|
|
|
$
|
12
|
|
|
|
|
Severance Costs
|
|
Lease Termination Expenses
|
|
Total
|
||||||
|
|
|
(in millions)
|
||||||||||
|
Balance at December 30, 2016
|
|
$
|
7
|
|
|
$
|
1
|
|
|
$
|
8
|
|
|
Charges
|
|
18
|
|
|
19
|
|
|
37
|
|
|||
|
Cash payments
|
|
(20
|
)
|
|
(16
|
)
|
|
(36
|
)
|
|||
|
Balance at December 29, 2017
|
|
5
|
|
|
4
|
|
|
9
|
|
|||
|
Charges
|
|
2
|
|
|
6
|
|
|
8
|
|
|||
|
Cash payments
|
|
(7
|
)
|
|
(8
|
)
|
|
(15
|
)
|
|||
|
Balance at December 28, 2018
|
|
$
|
—
|
|
|
$
|
2
|
|
|
$
|
2
|
|
|
|
|
December 28,
2018 |
|
December 29,
2017 |
||||
|
|
|
(in millions)
|
||||||
|
Billed receivables
(1)
|
|
$
|
1,067
|
|
|
$
|
771
|
|
|
Unbilled receivables
|
|
818
|
|
|
1,074
|
|
||
|
Allowance for doubtful accounts
|
|
(8
|
)
|
|
(14
|
)
|
||
|
|
|
$
|
1,877
|
|
|
$
|
1,831
|
|
|
|
|
Defense Solutions
|
|
Civil
|
|
Health
|
|
Total
|
||||||||
|
|
|
(in millions)
|
||||||||||||||
|
Goodwill at December 30, 2016
(1)
|
|
$
|
1,954
|
|
|
$
|
1,731
|
|
|
$
|
937
|
|
|
$
|
4,622
|
|
|
Adjustment to original purchase price allocation
|
|
94
|
|
|
259
|
|
|
(16
|
)
|
|
337
|
|
||||
|
Foreign currency translation adjustments
|
|
7
|
|
|
8
|
|
|
—
|
|
|
15
|
|
||||
|
Goodwill at December 29, 2017
(1)
|
|
2,055
|
|
|
1,998
|
|
|
921
|
|
|
4,974
|
|
||||
|
Foreign currency translation adjustments
|
|
(40
|
)
|
|
(11
|
)
|
|
—
|
|
|
(51
|
)
|
||||
|
Transfers to assets held for sale
|
|
—
|
|
|
(57
|
)
|
|
—
|
|
|
(57
|
)
|
||||
|
Adjustment to goodwill
|
|
—
|
|
|
(6
|
)
|
|
—
|
|
|
(6
|
)
|
||||
|
Goodwill at December 28, 2018
(1)
|
|
$
|
2,015
|
|
|
$
|
1,924
|
|
|
$
|
921
|
|
|
$
|
4,860
|
|
|
|
|
December 28, 2018
|
|
December 29, 2017
|
||||||||||||||||||||
|
|
|
Gross
carrying value |
|
Accumulated
amortization |
|
Net
carrying value |
|
Gross
carrying value |
|
Accumulated
amortization |
|
Net
carrying value |
||||||||||||
|
|
|
(in millions)
|
||||||||||||||||||||||
|
Finite-lived intangible assets:
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
|
Program and contract intangibles
|
|
$
|
1,003
|
|
|
$
|
(374
|
)
|
|
$
|
629
|
|
|
$
|
1,013
|
|
|
$
|
(187
|
)
|
|
$
|
826
|
|
|
Software and technology
|
|
93
|
|
|
(74
|
)
|
|
19
|
|
|
89
|
|
|
(64
|
)
|
|
25
|
|
||||||
|
Customer relationships
|
|
4
|
|
|
(4
|
)
|
|
—
|
|
|
4
|
|
|
(3
|
)
|
|
1
|
|
||||||
|
Backlog
|
|
—
|
|
|
—
|
|
|
—
|
|
|
158
|
|
|
(158
|
)
|
|
—
|
|
||||||
|
Total finite-lived intangible assets
|
|
1,100
|
|
|
(452
|
)
|
|
648
|
|
|
1,264
|
|
|
(412
|
)
|
|
852
|
|
||||||
|
Indefinite-lived intangible assets:
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
|
Trade names
|
|
4
|
|
|
—
|
|
|
4
|
|
|
4
|
|
|
—
|
|
|
4
|
|
||||||
|
Total intangible assets
|
|
$
|
1,104
|
|
|
$
|
(452
|
)
|
|
$
|
652
|
|
|
$
|
1,268
|
|
|
$
|
(412
|
)
|
|
$
|
856
|
|
|
Fiscal Year Ending
|
|
|
||
|
|
|
(in millions)
|
||
|
2019
|
|
$
|
171
|
|
|
2020
|
|
126
|
|
|
|
2021
|
|
106
|
|
|
|
2022
|
|
92
|
|
|
|
2023
|
|
73
|
|
|
|
2024 and thereafter
|
|
80
|
|
|
|
|
|
$
|
648
|
|
|
|
|
December 28,
2018 |
|
December 29,
2017 |
||||
|
|
|
(in millions)
|
||||||
|
Computers and other equipment
|
|
$
|
233
|
|
|
$
|
194
|
|
|
Leasehold improvements
|
|
206
|
|
|
171
|
|
||
|
Buildings and improvements
|
|
56
|
|
|
54
|
|
||
|
Land
|
|
40
|
|
|
49
|
|
||
|
Office furniture and fixtures
|
|
36
|
|
|
34
|
|
||
|
Construction in progress
|
|
15
|
|
|
44
|
|
||
|
|
|
586
|
|
|
546
|
|
||
|
Less: accumulated depreciation and amortization
|
|
(349
|
)
|
|
(314
|
)
|
||
|
|
|
$
|
237
|
|
|
$
|
232
|
|
|
|
|
December 28, 2018
|
|
December 29, 2017
|
||||||||||||
|
|
|
Carrying value
|
|
Fair value
|
|
Carrying value
|
|
Fair value
|
||||||||
|
|
|
(in millions)
|
||||||||||||||
|
Financial assets:
|
|
|
|
|
|
|
|
|
||||||||
|
Derivatives
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
37
|
|
|
$
|
37
|
|
|
Financial liabilities:
|
|
|
|
|
|
|
|
|
||||||||
|
Derivatives
|
|
35
|
|
|
35
|
|
|
—
|
|
|
—
|
|
||||
|
|
|
Asset derivatives
|
||||||||
|
|
|
Balance sheet line item
|
|
December 28,
2018 |
|
December 29,
2017 |
||||
|
|
|
|
|
(in millions)
|
||||||
|
Cash flow interest rate swaps
|
|
Other assets
|
|
$
|
—
|
|
|
$
|
37
|
|
|
|
|
Liability derivatives
|
||||||||
|
|
|
Balance sheet line item
|
|
December 28,
2018 |
|
December 29,
2017 |
||||
|
|
|
|
|
(in millions)
|
||||||
|
Fair value interest rate swaps
|
|
Other long-term liabilities
|
|
$
|
3
|
|
|
$
|
—
|
|
|
Cash flow interest rate swaps
|
|
Other long-term liabilities
|
|
32
|
|
|
—
|
|
||
|
|
|
|
|
$
|
35
|
|
|
$
|
—
|
|
|
|
|
Carrying amount of hedged item
|
|
Cumulative amount of fair value adjustment included within the hedged item
|
||||||||||||
|
Balance sheet line item of hedged item
|
|
December 28,
2018 |
|
December 29,
2017 |
|
December 28,
2018 |
|
December 29,
2017 |
||||||||
|
|
|
(in millions)
|
||||||||||||||
|
Long-term debt, net of current portion
|
|
$
|
447
|
|
|
$
|
449
|
|
|
$
|
(3
|
)
|
|
$
|
—
|
|
|
|
|
Year Ended
|
||||||||||
|
|
|
December 28,
2018 |
|
December 29,
2017 |
|
December 30,
2016 |
||||||
|
|
|
(in millions)
|
||||||||||
|
Total interest expense, net presented in the consolidated statements of income in which the effects of cash flow hedges are recorded
|
|
$
|
138
|
|
|
$
|
140
|
|
|
$
|
86
|
|
|
|
|
|
|
|
|
|
||||||
|
Amount recognized in other comprehensive (loss) income
|
|
(7
|
)
|
|
10
|
|
|
22
|
|
|||
|
Amount reclassified from accumulated other comprehensive (loss) income to interest expense, net
|
|
(6
|
)
|
|
—
|
|
|
2
|
|
|||
|
|
|
Stated
interest rate |
|
Effective
interest rate |
|
December 28, 2018
(1)
|
|
December 29, 2017
(1)
|
||||||
|
|
|
|
|
|
|
(in millions)
|
||||||||
|
Senior secured notes:
|
|
|
|
|
|
|
|
|
||||||
|
$450 million notes, due December 2020
|
|
4.45
|
%
|
|
4.53
|
%
|
|
$
|
447
|
|
|
$
|
449
|
|
|
$300 million notes, due December 2040
|
|
5.95
|
%
|
|
6.03
|
%
|
|
216
|
|
|
216
|
|
||
|
Senior secured term loans:
|
|
|
|
|
|
|
|
|
||||||
|
$690 million Term Loan A, due August 2023
|
|
3.88
|
%
|
|
4.31
|
%
|
|
617
|
|
|
644
|
|
||
|
$310 million Term Loan A, due August 2023
|
|
3.88
|
%
|
|
4.33
|
%
|
|
258
|
|
|
270
|
|
||
|
$1,131 million Term Loan B, due August 2025
|
|
4.13
|
%
|
|
4.48
|
%
|
|
1,085
|
|
|
1,101
|
|
||
|
Senior unsecured notes:
|
|
|
|
|
|
|
|
|
||||||
|
$250 million notes, due July 2032
|
|
7.13
|
%
|
|
7.43
|
%
|
|
246
|
|
|
246
|
|
||
|
$300 million notes, due July 2033
|
|
5.50
|
%
|
|
5.88
|
%
|
|
158
|
|
|
158
|
|
||
|
Notes payable and capital leases due on various dates through fiscal 2022
|
|
0%-5.55%
|
|
|
Various
|
|
|
97
|
|
|
27
|
|
||
|
Total long-term debt
|
|
|
|
|
|
3,124
|
|
|
3,111
|
|
||||
|
Less: current portion
|
|
|
|
|
|
72
|
|
|
55
|
|
||||
|
Total long-term debt, net of current portion
|
|
|
|
|
|
$
|
3,052
|
|
|
$
|
3,056
|
|
||
|
(1)
|
The carrying amounts of the senior secured term loans and notes and unsecured notes as of
December 28, 2018
, and
December 29, 2017
, include the remaining principal outstanding of
$3,073 million
and
$3,129 million
, respectively, less total unamortized debt discounts and deferred debt issuance costs of
$43 million
and
$45 million
, respectively, less
$3 million
related to the fair value of the interest rate swaps (see "
Note 14—Derivative Instruments
") as of
December 28, 2018
.
|
|
Fiscal Year Ending
|
|
|
||
|
|
|
(in millions)
|
||
|
2019
|
|
$
|
79
|
|
|
2020
|
|
509
|
|
|
|
2021
|
|
181
|
|
|
|
2022
|
|
102
|
|
|
|
2023
|
|
619
|
|
|
|
2024 and thereafter
|
|
1,677
|
|
|
|
Total principal payments
|
|
3,167
|
|
|
|
Less: unamortized debt discount and issuance costs
|
|
(43
|
)
|
|
|
Total long-term debt
|
|
$
|
3,124
|
|
|
|
|
Foreign currency translation adjustments
|
|
Unrecognized (loss) gain on derivative instruments
|
|
Pension adjustments
|
|
Total accumulated other comprehensive (loss) income
|
||||||||
|
|
|
(in millions)
|
||||||||||||||
|
Balance at January 1, 2016
|
|
$
|
—
|
|
|
$
|
(4
|
)
|
|
$
|
(4
|
)
|
|
$
|
(8
|
)
|
|
Other comprehensive (loss) income
|
|
(8
|
)
|
|
26
|
|
|
1
|
|
|
19
|
|
||||
|
Taxes
|
|
1
|
|
|
(10
|
)
|
|
2
|
|
|
(7
|
)
|
||||
|
Reclassification from accumulated other comprehensive (loss) income
|
|
—
|
|
|
(2
|
)
|
|
(6
|
)
|
|
(8
|
)
|
||||
|
Balance at December 30, 2016
|
|
(7
|
)
|
|
10
|
|
|
(7
|
)
|
|
(4
|
)
|
||||
|
Other comprehensive income
|
|
36
|
|
|
10
|
|
|
9
|
|
|
55
|
|
||||
|
Taxes
|
|
(12
|
)
|
|
(6
|
)
|
|
—
|
|
|
(18
|
)
|
||||
|
Balance at December 29, 2017
|
|
17
|
|
|
14
|
|
|
2
|
|
|
33
|
|
||||
|
Cumulative adjustments related to ASU adoptions (Note 2)
|
|
3
|
|
|
10
|
|
|
(4
|
)
|
|
9
|
|
||||
|
Balance at December 30, 2017
|
|
20
|
|
|
24
|
|
|
(2
|
)
|
|
42
|
|
||||
|
Other comprehensive loss
|
|
(65
|
)
|
|
(7
|
)
|
|
(1
|
)
|
|
(73
|
)
|
||||
|
Taxes
|
|
4
|
|
|
3
|
|
|
—
|
|
|
7
|
|
||||
|
Reclassification from accumulated other comprehensive (loss) income
|
|
—
|
|
|
(6
|
)
|
|
—
|
|
|
(6
|
)
|
||||
|
Balance at December 28, 2018
|
|
$
|
(41
|
)
|
|
$
|
14
|
|
|
$
|
(3
|
)
|
|
$
|
(30
|
)
|
|
Balance Sheet
|
|
December 28,
2018 |
|
December 29,
2017 |
||||
|
|
|
(in millions)
|
||||||
|
Other current assets:
|
|
|
|
|
||||
|
Transition costs and project assets
(1)(2)
|
|
$
|
145
|
|
|
$
|
87
|
|
|
Pre-contract costs
|
|
41
|
|
|
64
|
|
||
|
Other
(4)
|
|
357
|
|
|
302
|
|
||
|
|
|
$
|
543
|
|
|
$
|
453
|
|
|
Other assets:
|
|
|
|
|
||||
|
Equity method investments
(3)
|
|
$
|
26
|
|
|
$
|
37
|
|
|
Other
(4)
|
|
156
|
|
|
217
|
|
||
|
|
|
$
|
182
|
|
|
$
|
254
|
|
|
Accounts payable and accrued liabilities:
|
|
|
|
|
||||
|
Accrued liabilities
|
|
$
|
650
|
|
|
$
|
747
|
|
|
Accounts payable
|
|
547
|
|
|
557
|
|
||
|
Deferred revenue
|
|
276
|
|
|
293
|
|
||
|
Other
|
|
3
|
|
|
42
|
|
||
|
|
|
$
|
1,476
|
|
|
$
|
1,639
|
|
|
Accrued payroll and employee benefits:
|
|
|
|
|
||||
|
Salaries, bonuses and amounts withheld from employees’ compensation
|
|
$
|
248
|
|
|
$
|
245
|
|
|
Accrued vacation
|
|
225
|
|
|
236
|
|
||
|
Other
|
|
—
|
|
|
6
|
|
||
|
|
|
$
|
473
|
|
|
$
|
487
|
|
|
|
|
Year Ended
|
||||||||||
|
Income Statement
|
|
December 28,
2018 |
|
December 29,
2017 |
|
December 30,
2016 |
||||||
|
|
|
(in millions)
|
||||||||||
|
Interest expense, net:
|
|
|
|
|
|
|
||||||
|
Interest expense
|
|
$
|
(145
|
)
|
|
$
|
(148
|
)
|
|
$
|
(96
|
)
|
|
Interest income
|
|
7
|
|
|
8
|
|
|
10
|
|
|||
|
|
|
$
|
(138
|
)
|
|
$
|
(140
|
)
|
|
$
|
(86
|
)
|
|
Other expense, net
|
|
|
|
|
|
|
||||||
|
Promissory note impairment
|
|
$
|
—
|
|
|
$
|
(33
|
)
|
|
$
|
—
|
|
|
Gain (loss) on foreign currencies
|
|
2
|
|
|
5
|
|
|
(18
|
)
|
|||
|
Other (expense) income, net
|
|
(3
|
)
|
|
2
|
|
|
5
|
|
|||
|
|
|
$
|
(1
|
)
|
|
$
|
(26
|
)
|
|
$
|
(13
|
)
|
|
|
|
Year Ended
|
|||||||
|
|
|
December 28,
2018 |
|
December 29,
2017 |
|
December 30,
2016 |
|||
|
|
|
(in millions)
|
|||||||
|
Basic weighted average number of shares outstanding
|
|
151
|
|
|
152
|
|
|
102
|
|
|
Dilutive common share equivalents—stock options and other stock awards
|
|
2
|
|
|
2
|
|
|
2
|
|
|
Diluted weighted average number of shares outstanding
|
|
153
|
|
|
154
|
|
|
104
|
|
|
|
|
Year Ended
|
||||||||||
|
|
|
December 28,
2018 |
|
December 29,
2017 |
|
December 30,
2016 |
||||||
|
|
|
(in millions)
|
||||||||||
|
Total stock-based compensation expense
|
|
$
|
44
|
|
|
$
|
43
|
|
|
$
|
35
|
|
|
Tax benefits recognized from stock-based compensation
|
|
11
|
|
|
17
|
|
|
14
|
|
|||
|
|
|
Year Ended
|
||||||||||||||
|
|
|
December 28,
2018 |
|
December 29,
2017 |
|
December 30, 2016
(Grants after acquisition) |
|
December 30, 2016
(Grants before acquisition) |
||||||||
|
Weighted average grant-date fair value
|
|
$
|
13.85
|
|
|
$
|
11.53
|
|
|
$
|
10.33
|
|
|
$
|
9.54
|
|
|
Expected term (in years)
|
|
4.7
|
|
|
4.7
|
|
|
4.7
|
|
|
4.8
|
|
||||
|
Expected volatility
|
|
26.6
|
%
|
|
29.7
|
%
|
|
37.9
|
%
|
|
29.9
|
%
|
||||
|
Risk-free interest rate
|
|
2.6
|
%
|
|
1.9
|
%
|
|
1.2
|
%
|
|
1.3
|
%
|
||||
|
Dividend yield
|
|
2.0
|
%
|
|
2.5
|
%
|
|
2.7
|
%
|
|
2.5
|
%
|
||||
|
|
|
Shares of
stock under
stock options
|
|
Weighted
average
exercise price
|
|
Weighted
average
remaining
contractual
term
|
|
Aggregate
intrinsic value
|
|||||
|
|
|
(in millions)
|
|
|
|
(in years)
|
|
(in millions)
|
|||||
|
Outstanding at January 1, 2016
|
|
2.4
|
|
|
$
|
38.21
|
|
|
4.5
|
|
$
|
43
|
|
|
Options granted
|
|
0.6
|
|
|
43.56
|
|
|
|
|
|
|||
|
Special dividend adjustments
|
|
0.9
|
|
|
|
|
|
|
|
||||
|
Options forfeited or expired
|
|
(0.2
|
)
|
|
34.98
|
|
|
|
|
|
|||
|
Options exercised
|
|
(0.4
|
)
|
|
34.11
|
|
|
|
|
5
|
|
||
|
Outstanding at December 30, 2016
|
|
3.3
|
|
|
$
|
29.77
|
|
|
4.1
|
|
$
|
70
|
|
|
Options granted
|
|
0.5
|
|
|
53.51
|
|
|
|
|
|
|||
|
Options forfeited or expired
|
|
(0.2
|
)
|
|
35.72
|
|
|
|
|
|
|||
|
Options exercised
|
|
(0.8
|
)
|
|
27.23
|
|
|
|
|
23
|
|
||
|
Outstanding at December 29, 2017
|
|
2.8
|
|
|
$
|
34.38
|
|
|
3.9
|
|
$
|
86
|
|
|
Options granted
|
|
0.4
|
|
|
63.75
|
|
|
|
|
|
|
||
|
Options forfeited or expired
|
|
(0.2
|
)
|
|
49.65
|
|
|
|
|
|
|
||
|
Options exercised
|
|
(0.6
|
)
|
|
30.40
|
|
|
|
|
24
|
|
||
|
Outstanding at December 28, 2018
|
|
2.4
|
|
|
39.41
|
|
|
3.8
|
|
36
|
|
||
|
Exercisable at December 28, 2018
|
|
1.4
|
|
|
$
|
31.72
|
|
|
2.8
|
|
$
|
29
|
|
|
Vested and expected to vest in the future as of December 28, 2018
|
|
2.4
|
|
|
$
|
39.15
|
|
|
3.7
|
|
$
|
36
|
|
|
|
|
Shares of stock
under stock
awards
|
|
Weighted
average grant-
date fair value
|
|||
|
|
|
(in millions)
|
|
|
|||
|
Unvested stock awards at January 1, 2016
|
|
2.3
|
|
|
$
|
38.97
|
|
|
Awards granted
|
|
1.5
|
|
|
41.45
|
|
|
|
Awards forfeited
|
|
(0.2
|
)
|
|
40.88
|
|
|
|
Awards vested
|
|
(1.1
|
)
|
|
38.91
|
|
|
|
Unvested stock awards at December 30, 2016
|
|
2.5
|
|
|
$
|
40.39
|
|
|
Awards granted
|
|
0.8
|
|
|
53.91
|
|
|
|
Awards forfeited
|
|
(0.3
|
)
|
|
45.89
|
|
|
|
Awards vested
|
|
(1.0
|
)
|
|
41.02
|
|
|
|
Unvested stock awards at December 29, 2017
|
|
2.0
|
|
|
$
|
44.96
|
|
|
Awards granted
|
|
0.6
|
|
|
64.05
|
|
|
|
Awards forfeited
|
|
(0.2
|
)
|
|
42.67
|
|
|
|
Awards vested
|
|
(0.4
|
)
|
|
44.60
|
|
|
|
Unvested stock awards at December 28, 2018
|
|
2.0
|
|
|
$
|
50.85
|
|
|
|
|
Expected number
of shares of stock
to be issued under
performance-based
stock awards
|
|
Weighted
average grant-
date fair value
|
|||
|
|
|
(in millions)
|
|
|
|||
|
Unvested at January 1, 2016
|
|
0.2
|
|
|
$
|
43.35
|
|
|
Awards granted
|
|
0.2
|
|
|
45.62
|
|
|
|
Unvested at December 30, 2016
|
|
0.4
|
|
|
$
|
44.44
|
|
|
Awards granted
|
|
0.2
|
|
|
57.94
|
|
|
|
Awards vested
|
|
(0.1
|
)
|
|
42.85
|
|
|
|
Unvested at December 29, 2017
|
|
0.5
|
|
|
$
|
50.34
|
|
|
Awards granted
|
|
0.3
|
|
|
61.43
|
|
|
|
Awards forfeited
|
|
(0.1
|
)
|
|
61.81
|
|
|
|
Awards vested
|
|
(0.2
|
)
|
|
44.04
|
|
|
|
Unvested at December 28, 2018
|
|
0.5
|
|
|
$
|
57.36
|
|
|
|
|
Year Ended
|
||||||||||
|
|
|
December 28,
2018 |
|
December 29,
2017 |
|
December 30,
2016 |
||||||
|
Expected volatility
|
|
25.37
|
%
|
|
27.19
|
%
|
|
31.73
|
%
|
|||
|
Risk free rate of return
|
|
2.35
|
%
|
|
1.53
|
%
|
|
1.01
|
%
|
|||
|
Weighted average grant date stock price
|
|
$
|
65.00
|
|
|
$
|
53.73
|
|
|
$
|
46.54
|
|
|
|
|
Year Ended
|
||||||||||
|
|
|
December 28,
2018 |
|
December 29,
2017 |
|
December 30,
2016 |
||||||
|
|
|
(in millions)
|
||||||||||
|
Current:
|
|
|
|
|
|
|
||||||
|
Federal and foreign
|
|
$
|
54
|
|
|
$
|
130
|
|
|
$
|
88
|
|
|
State
|
|
23
|
|
|
30
|
|
|
16
|
|
|||
|
Deferred:
|
|
|
|
|
|
|
||||||
|
Federal and foreign
|
|
(39
|
)
|
|
(141
|
)
|
|
(29
|
)
|
|||
|
State
|
|
(10
|
)
|
|
10
|
|
|
(3
|
)
|
|||
|
Total
|
|
$
|
28
|
|
|
$
|
29
|
|
|
$
|
72
|
|
|
|
|
Year Ended
|
||||||||||
|
|
|
December 28,
2018 |
|
December 29,
2017 |
|
December 30,
2016 |
||||||
|
|
|
(in millions)
|
||||||||||
|
Amount computed at the statutory federal income tax rate
|
|
$
|
128
|
|
|
$
|
138
|
|
|
$
|
111
|
|
|
State income taxes, net of federal tax benefit
|
|
10
|
|
|
31
|
|
|
8
|
|
|||
|
Change in valuation allowance for deferred tax assets
|
|
(49
|
)
|
|
7
|
|
|
(8
|
)
|
|||
|
Taxable conversion of a subsidiary
|
|
(17
|
)
|
|
—
|
|
|
—
|
|
|||
|
Stock basis in subsidiary held for sale
|
|
(16
|
)
|
|
—
|
|
|
—
|
|
|||
|
Change in statutory federal tax rate
|
|
(10
|
)
|
|
(125
|
)
|
|
—
|
|
|||
|
Excess tax benefits from stock-based compensation
|
|
(9
|
)
|
|
(12
|
)
|
|
(8
|
)
|
|||
|
Research and development credits
|
|
(9
|
)
|
|
(7
|
)
|
|
(4
|
)
|
|||
|
Dividends paid to employee stock ownership plan
|
|
(2
|
)
|
|
(4
|
)
|
|
(38
|
)
|
|||
|
Change in accruals for uncertain tax positions
|
|
1
|
|
|
—
|
|
|
1
|
|
|||
|
Capitalized transaction costs
|
|
—
|
|
|
9
|
|
|
7
|
|
|||
|
Impact of foreign operations
|
|
—
|
|
|
(4
|
)
|
|
—
|
|
|||
|
Other
|
|
1
|
|
|
(4
|
)
|
|
3
|
|
|||
|
Total
|
|
$
|
28
|
|
|
$
|
29
|
|
|
$
|
72
|
|
|
Effective income tax rate
|
|
4.6
|
%
|
|
7.4
|
%
|
|
22.6
|
%
|
|||
|
|
|
December 28,
2018 |
|
December 29,
2017 |
||||
|
|
|
(in millions)
|
||||||
|
Reserves
|
|
$
|
57
|
|
|
$
|
62
|
|
|
Accrued vacation and bonuses
|
|
48
|
|
|
54
|
|
||
|
Credits and net operating losses carryovers
|
|
31
|
|
|
33
|
|
||
|
Deferred compensation
|
|
25
|
|
|
22
|
|
||
|
Vesting stock awards
|
|
20
|
|
|
17
|
|
||
|
Deferred gain
|
|
20
|
|
|
—
|
|
||
|
Deferred rent and tenant allowances
|
|
18
|
|
|
10
|
|
||
|
Investments
|
|
18
|
|
|
2
|
|
||
|
Capital loss carryover
|
|
—
|
|
|
60
|
|
||
|
Other
|
|
13
|
|
|
18
|
|
||
|
Total deferred tax assets
|
|
250
|
|
|
278
|
|
||
|
Valuation allowance
|
|
(28
|
)
|
|
(83
|
)
|
||
|
Deferred tax assets, net of valuation allowance
|
|
222
|
|
|
195
|
|
||
|
|
|
|
|
|
||||
|
Purchased intangible assets
|
|
(326
|
)
|
|
(340
|
)
|
||
|
Deferred revenue
|
|
(40
|
)
|
|
(34
|
)
|
||
|
Accumulated other comprehensive (loss) income
|
|
(6
|
)
|
|
(13
|
)
|
||
|
Employee benefit contributions
|
|
(4
|
)
|
|
(3
|
)
|
||
|
Partnership interest
|
|
(2
|
)
|
|
(17
|
)
|
||
|
Other
|
|
(14
|
)
|
|
(8
|
)
|
||
|
Total deferred tax liabilities
|
|
(392
|
)
|
|
(415
|
)
|
||
|
Net deferred tax liabilities
|
|
$
|
(170
|
)
|
|
$
|
(220
|
)
|
|
|
|
December 28,
2018 |
|
December 29,
2017 |
||||
|
|
|
(in millions)
|
||||||
|
Other current assets:
|
|
|
|
|
||||
|
Prepaid income taxes and tax refunds receivable
|
|
$
|
43
|
|
|
$
|
54
|
|
|
Income taxes payable
|
|
3
|
|
|
4
|
|
||
|
Deferred tax liabilities
|
|
170
|
|
|
220
|
|
||
|
Other long-term liabilities:
|
|
|
|
|
||||
|
Unrecognized tax benefits
|
|
3
|
|
|
9
|
|
||
|
|
|
Year Ended
|
||||||||||
|
|
|
December 28,
2018 |
|
December 29,
2017 |
|
December 30,
2016 |
||||||
|
|
|
(in millions)
|
||||||||||
|
Unrecognized tax benefits at beginning of year
|
|
$
|
10
|
|
|
$
|
9
|
|
|
$
|
11
|
|
|
Additions for tax positions related to current year
|
|
3
|
|
|
2
|
|
|
1
|
|
|||
|
Additions for tax positions related to prior years
|
|
—
|
|
|
2
|
|
|
4
|
|
|||
|
Reductions for tax positions related to prior years
|
|
(7
|
)
|
|
(3
|
)
|
|
(7
|
)
|
|||
|
Unrecognized tax benefits at end of year
|
|
$
|
6
|
|
|
$
|
10
|
|
|
$
|
9
|
|
|
Unrecognized tax benefits that, if recognized, would affect the effective income tax rate
|
|
$
|
6
|
|
|
$
|
7
|
|
|
$
|
4
|
|
|
|
|
Year Ended
|
||||||||||
|
|
|
December 28,
2018 |
|
December 29,
2017 |
|
December 30,
2016 |
||||||
|
|
|
(in millions)
|
||||||||||
|
Gross rental expense
|
|
$
|
163
|
|
|
$
|
181
|
|
|
$
|
107
|
|
|
Less: sublease income
|
|
(1
|
)
|
|
(3
|
)
|
|
(2
|
)
|
|||
|
Net rental expense
|
|
$
|
162
|
|
|
$
|
178
|
|
|
$
|
105
|
|
|
Fiscal Year Ending
|
|
Operating lease
commitment |
|
Sublease
receipts |
||||
|
|
|
(in millions)
|
||||||
|
2019
|
|
$
|
144
|
|
|
$
|
3
|
|
|
2020
|
|
114
|
|
|
1
|
|
||
|
2021
|
|
83
|
|
|
1
|
|
||
|
2022
|
|
71
|
|
|
—
|
|
||
|
2023
|
|
55
|
|
|
—
|
|
||
|
2024 and thereafter
|
|
246
|
|
|
—
|
|
||
|
Total
|
|
$
|
713
|
|
|
$
|
5
|
|
|
|
|
Year Ended
|
||||||||||
|
|
|
December 28,
2018 |
|
December 29,
2017 |
|
December 30,
2016 |
||||||
|
|
|
(in millions)
|
||||||||||
|
Supplementary cash flow information:
|
|
|
|
|
|
|
||||||
|
Cash paid for interest
|
|
$
|
133
|
|
|
$
|
133
|
|
|
$
|
90
|
|
|
Cash paid for income taxes, net of refunds
|
|
70
|
|
|
214
|
|
|
47
|
|
|||
|
|
|
|
|
|
|
|
||||||
|
Non-cash investing activity:
|
|
|
|
|
|
|
||||||
|
Stock issued for acquisition of the IS&GS Business
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
2,938
|
|
|
|
|
|
|
|
|
|
||||||
|
Non-cash financing activity:
|
|
|
|
|
|
|
||||||
|
Real estate financing transaction
|
|
$
|
65
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
Dividends declared
|
|
3
|
|
|
3
|
|
|
21
|
|
|||
|
Notes payable and capital lease obligations
|
|
—
|
|
|
27
|
|
|
—
|
|
|||
|
|
|
December 28,
2018 |
|
December 29,
2017 |
||||
|
|
|
(in millions)
|
||||||
|
Cash and cash equivalents
|
|
$
|
327
|
|
|
$
|
390
|
|
|
Restricted cash
|
|
42
|
|
|
32
|
|
||
|
Total cash, cash equivalents and restricted cash
|
|
$
|
369
|
|
|
$
|
422
|
|
|
|
|
Year Ended
|
||||||||||
|
|
|
December 28,
2018 |
|
December 29,
2017 |
|
December 30,
2016 |
||||||
|
|
|
(in millions)
|
||||||||||
|
Revenues:
|
|
|
|
|
|
|
||||||
|
Defense Solutions
|
|
$
|
4,948
|
|
|
$
|
4,959
|
|
|
$
|
3,843
|
|
|
Civil
|
|
3,429
|
|
|
3,409
|
|
|
2,082
|
|
|||
|
Health
|
|
1,817
|
|
|
1,802
|
|
|
1,117
|
|
|||
|
Corporate
|
|
—
|
|
|
—
|
|
|
1
|
|
|||
|
Total revenues
|
|
$
|
10,194
|
|
|
$
|
10,170
|
|
|
$
|
7,043
|
|
|
|
|
|
|
|
|
|
||||||
|
Operating income (loss):
|
|
|
|
|
|
|
||||||
|
Defense Solutions
|
|
$
|
347
|
|
|
$
|
307
|
|
|
$
|
312
|
|
|
Civil
|
|
290
|
|
|
226
|
|
|
146
|
|
|||
|
Health
|
|
230
|
|
|
228
|
|
|
110
|
|
|||
|
Corporate
|
|
(118
|
)
|
|
(202
|
)
|
|
(151
|
)
|
|||
|
Total operating income
|
|
$
|
749
|
|
|
$
|
559
|
|
|
$
|
417
|
|
|
|
|
|
|
|
|
|
||||||
|
Amortization of intangible assets:
|
|
|
|
|
|
|
||||||
|
Defense Solutions
|
|
$
|
68
|
|
|
$
|
108
|
|
|
$
|
17
|
|
|
Civil
|
|
87
|
|
|
132
|
|
|
39
|
|
|||
|
Health
|
|
46
|
|
|
41
|
|
|
28
|
|
|||
|
Total amortization of intangible assets
|
|
$
|
201
|
|
|
$
|
281
|
|
|
$
|
84
|
|
|
|
|
Year Ended
|
|||||||
|
|
|
December 28,
2018 |
|
December 29,
2017 |
|
December 30,
2016 |
|||
|
U.S. Government
|
|
85
|
%
|
|
84
|
%
|
|
81
|
%
|
|
U.S. DoD
|
|
47
|
%
|
|
47
|
%
|
|
56
|
%
|
|
U.S. Army
|
|
13
|
%
|
|
13
|
%
|
|
14
|
%
|
|
|
|
Three Months Ended
|
||||||||||||||
|
|
|
March 30,
2018 |
|
June 29,
2018 |
|
September 28,
2018 |
|
December 28,
2018 |
||||||||
|
|
|
(in millions, except per share amounts)
|
||||||||||||||
|
Fiscal 2018
(1)
|
|
|
|
|
|
|
|
|
||||||||
|
Revenues
|
|
$
|
2,443
|
|
|
$
|
2,529
|
|
|
$
|
2,575
|
|
|
$
|
2,647
|
|
|
Operating income
|
|
159
|
|
|
199
|
|
|
203
|
|
|
188
|
|
||||
|
Net income
|
|
102
|
|
|
145
|
|
|
147
|
|
|
188
|
|
||||
|
Net income attributable to Leidos common stockholders
|
|
102
|
|
|
144
|
|
|
147
|
|
|
188
|
|
||||
|
Basic earnings per share attributable to Leidos common stockholders
(3)
|
|
$
|
0.67
|
|
|
$
|
0.95
|
|
|
$
|
0.97
|
|
|
$
|
1.27
|
|
|
Diluted earnings per share attributable to Leidos common stockholders
(3)
|
|
0.66
|
|
|
0.94
|
|
|
0.96
|
|
|
1.25
|
|
||||
|
|
|
Three Months Ended
|
||||||||||||||
|
|
|
March 31,
2017 |
|
June 30,
2017 |
|
September 29,
2017 |
|
December 29,
2017 |
||||||||
|
|
|
(in millions, except per share amounts)
|
||||||||||||||
|
Fiscal 2017
(2)
|
|
|
|
|
|
|
|
|
||||||||
|
Revenues
|
|
$
|
2,580
|
|
|
$
|
2,571
|
|
|
$
|
2,503
|
|
|
$
|
2,516
|
|
|
Operating income
|
|
141
|
|
|
166
|
|
|
151
|
|
|
101
|
|
||||
|
Net income
|
|
74
|
|
|
98
|
|
|
79
|
|
|
113
|
|
||||
|
Net income attributable to Leidos common stockholders
|
|
72
|
|
|
98
|
|
|
82
|
|
|
114
|
|
||||
|
Basic earnings per share attributable to Leidos common stockholders
(3)
|
|
$
|
0.48
|
|
|
$
|
0.65
|
|
|
$
|
0.54
|
|
|
$
|
0.75
|
|
|
Diluted earnings per share attributable to Leidos common stockholders
(3)
|
|
0.47
|
|
|
0.64
|
|
|
0.53
|
|
|
0.74
|
|
||||
|
(1)
|
The fiscal
2018
quarterly results include acquisition, integration and restructuring costs of
$17 million
,
$8 million
,
$7 million
, and
$5 million
in the first, second, third and fourth quarter, respectively. The fiscal 2018 first quarter results include a
$7 million
tangible asset impairment charge.
|
|
(2)
|
The fiscal
2017
quarterly results include acquisition, integration and restructuring costs of
$32 million
,
$22 million
,
$27 million
, and
$58 million
in the first, second, third, and fourth quarter, respectively. The fiscal
2017
fourth quarter results include a
$33 million
promissory note impairment charge.
|
|
(3)
|
Earnings per share are computed independently for each of the quarters presented and therefore may not sum to the totals for fiscal
2018
and
2017
.
|
|
Plan Category
|
|
(a)
Number of securities
to be issued upon
exercise of
outstanding options,
warrants and rights
|
|
(b)
Weighted-average
exercise price of
outstanding
options, warrants
and rights
|
|
(c)
Number of securities
remaining available
for future issuance
under equity
compensation
plans (excluding
securities reflected
in column (a))
|
|
||||
|
Equity compensation plans approved by security holders
(1)
|
|
4,961,505
|
|
(2)
|
$
|
39.41
|
|
(3)
|
14,031,561
|
|
(4)
|
|
Equity compensation plans not approved by security holders
(5)
|
|
—
|
|
|
—
|
|
|
—
|
|
(5)
|
|
|
Total
|
|
4,961,505
|
|
(2)
|
$
|
39.41
|
|
(3)
|
14,031,561
|
|
|
|
(1)
|
The following equity compensation plans approved by security holders are included in this plan category: the 2017 Omnibus Incentive Plan, the 2006 Equity Incentive Plan, as amended, and the 2006 Employee Stock Purchase Plan, as amended.
|
|
(2)
|
Represents (i)
2,493,594
shares of Leidos common stock reserved for future issuance for service-based awards and performance and market-based awards assuming achievement of the target level of performance for unearned performance and market-based awards (does not include an additional
244,927
shares if the maximum level of performance is achieved) and other stock awards under the 2017 Omnibus Incentive Plan and 2006 Equity Incentive Plan, (ii)
37,995
shares of Leidos common stock issuable pursuant to dividend equivalent rights for deferred awards and (iii)
2,429,916
shares of Leidos common stock reserved for future issuance upon the exercise of outstanding options awarded under the 2017 Omnibus Incentive Plan and 2006 Equity Incentive Plan. Does not include shares to be issued pursuant to purchase rights under the 2006 Employee Stock Purchase Plan.
|
|
(3)
|
Does not include shares to be issued for performance-based and other stock awards and shares of stock issuable pursuant to dividend equivalent rights.
|
|
(4)
|
Represents
9,433,178
and
4,598,383
shares of Leidos common stock under the 2017 Omnibus Incentive Plan and 2006 Employee Stock Purchase Plan, respectively. The maximum number of shares initially available for issuance under the 2017 Omnibus Incentive Plan was
7.5 million
. The 2006 Equity Incentive Plan was amended in June 2012 to provide that the maximum number of shares available for issuance thereunder is
12.5 million
. The 2006 Employee Stock Purchase Plan was amended in September 2016 to provide that the maximum number of shares available for issuance thereunder is
5.0 million
. Those shares (i) that are issued under the 2017 Omnibus Incentive Plan and 2006 Equity Incentive Plan that are forfeited or repurchased at the original purchase price or less or that are issuable upon exercise of awards granted under the plan that expire or become unexercisable for any reason after their grant date without having been exercised in full, (ii) that are withheld from an option or stock award pursuant to a Company-approved net exercise provision, or (iii) that are not delivered to or are award shares surrendered by a holder in consideration for applicable tax withholding will continue to be available for issuance under the 2017 Omnibus Incentive Plan.
|
|
(5)
|
The Management Stock Compensation Plan has not been approved by security holders and is included in this plan category. This plan does not provide for a maximum number of shares available for future issuance. For further information on this plan, see "
Note 19—Stock-Based Compensation
" of the notes to the consolidated financial statements contained within Part II of this Annual Report on Form 10-K.
|
|
Exhibit
Number |
|
Description of Exhibit
|
|
2.1
|
|
|
|
|
|
|
|
2.2
|
|
|
|
|
|
|
|
2.3
|
|
|
|
|
|
|
|
2.4
|
|
|
|
|
|
|
|
2.5
|
|
|
|
|
|
|
|
3.1
|
|
|
|
|
|
|
|
3.2
|
|
|
|
|
|
|
|
4.1**
|
|
Indenture dated June 28, 2002, between Leidos, Inc. and JPMorgan Chase Bank, as trustee. Incorporated by reference to Exhibit 4.2 to our Current Report on Form 8-K filed with the SEC on July 3, 2002. (SEC File No. 000-12771)
|
|
|
|
|
|
4.2
|
|
|
|
|
|
|
|
4.3
|
|
|
|
|
|
|
|
|
|
|
|
10.1*
|
|
|
|
|
|
|
|
10.2*
|
|
|
|
Exhibit
Number |
|
Description of Exhibit
|
|
|
|
|
|
10.3*
|
|
|
|
|
|
|
|
10.4*
|
|
|
|
|
|
|
|
10.5*
|
|
|
|
|
|
|
|
10.6*
|
|
|
|
|
|
|
|
10.7*
|
|
|
|
|
|
|
|
10.8*
|
|
|
|
|
|
|
|
10.9*
|
|
|
|
|
|
|
|
10.10*
|
|
|
|
|
|
|
|
10.11*
|
|
|
|
|
|
|
|
10.12*
|
|
|
|
|
|
|
|
10.13*
|
|
|
|
|
|
|
|
10.14*
|
|
|
|
|
|
|
|
10.15*
|
|
|
|
|
|
|
|
10.16*
|
|
|
|
|
|
|
|
10.17*
|
|
|
|
|
|
|
|
10.18*
|
|
|
|
|
|
|
|
10.19*
|
|
|
|
|
|
|
|
10.20*
|
|
|
|
|
|
|
|
Exhibit
Number |
|
Description of Exhibit
|
|
10.21*
|
|
|
|
|
|
|
|
10.22*
|
|
|
|
|
|
|
|
10.23*
|
|
|
|
|
|
|
|
10.24*
|
|
|
|
|
|
|
|
10.25*
|
|
|
|
|
|
|
|
10.26
|
|
|
|
|
|
|
|
10.27
|
|
|
|
|
|
|
|
10.28
|
|
|
|
|
|
|
|
10.29
|
|
|
|
|
|
|
|
10.30
|
|
|
|
|
|
|
|
10.31
|
|
|
|
10.32
|
|
|
|
|
|
|
|
10.33
|
|
|
|
|
|
|
|
10.34
|
|
|
|
|
|
|
|
Exhibit
Number |
|
Description of Exhibit
|
|
10.35
|
|
|
|
10.36
|
|
|
|
10.37
|
|
|
|
10.38
|
|
|
|
|
|
|
|
10.39
|
|
|
|
|
|
|
|
10.40
|
|
|
|
|
|
|
|
10.41
|
|
|
|
|
|
|
|
10.42
|
|
|
|
|
|
|
|
10.43
|
|
|
|
|
|
|
|
10.44
|
|
|
|
|
|
|
|
21
|
|
|
|
|
|
|
|
23.1
|
|
|
|
|
|
|
|
31.1
|
|
|
|
|
|
|
|
31.2
|
|
|
|
|
|
|
|
32.1
|
|
|
|
|
|
|
|
32.2
|
|
|
|
|
|
|
|
99.1
|
|
|
|
|
|
|
|
Exhibit
Number |
|
Description of Exhibit
|
|
99.2†
|
|
|
|
|
|
|
|
99.3
|
|
|
|
|
|
|
|
99.4
|
|
|
|
|
|
|
|
99.5
|
|
|
|
|
|
|
|
99.6
|
|
|
|
|
|
|
|
99.7†
|
|
|
|
|
|
|
|
101
|
|
Interactive Data File.
|
|
*
|
Executive Compensation Plans and Arrangements
|
|
†
|
Confidential treatment has been granted with respect to certain portions of these exhibits
|
|
Leidos Holdings, Inc.
|
|
|
|
|
|
By
|
/s/ James C. Reagan
|
|
|
James C. Reagan
Executive Vice President and Chief Financial Officer
|
|
Signature
|
Title
|
Date
|
|
|
|
|
|
/s/ Roger A. Krone
|
Principal Executive Officer
|
February 19, 2019
|
|
Roger A. Krone
|
||
|
|
|
|
|
/s/ James C. Reagan
|
Principal Financial Officer
|
February 19, 2019
|
|
James C. Reagan
|
||
|
|
|
|
|
/s/ Ranjit S. Chadha
|
Principal Accounting Officer
|
February 19, 2019
|
|
Ranjit S. Chadha
|
||
|
|
|
|
|
/s/ Gregory R. Dahlberg
|
Director
|
February 19, 2019
|
|
Gregory R. Dahlberg
|
||
|
|
|
|
|
/s/ David G. Fubini
|
Director
|
February 19, 2019
|
|
David G. Fubini
|
||
|
|
|
|
|
/s/ Miriam E. John
|
Director
|
February 19, 2019
|
|
Miriam E. John
|
||
|
|
|
|
|
/s/ Frank Kendall III
|
Director
|
February 19, 2019
|
|
Frank Kendall III
|
||
|
|
|
|
|
/s/ Robert C. Kovarik, Jr.
|
Director
|
February 19, 2019
|
|
Robert C. Kovarik, Jr.
|
||
|
|
|
|
|
/s/ Harry M. J. Kraemer, Jr.
|
Director
|
February 19, 2019
|
|
Harry M. J. Kraemer, Jr.
|
||
|
|
|
|
|
/s/ Gary S. May
|
Director
|
February 19, 2019
|
|
Gary S. May
|
||
|
|
|
|
|
/s/ Surya N. Mohapatra
|
Director
|
February 19, 2019
|
|
Surya N. Mohapatra
|
||
|
|
|
|
|
/s/ Lawrence C. Nussdorf
|
Director
|
February 19, 2019
|
|
Lawrence C. Nussdorf
|
||
|
|
|
|
|
/s/ Robert S. Shapard
|
Director
|
February 19, 2019
|
|
Robert S. Shapard
|
||
|
|
|
|
|
/s/ Susan M. Stalnecker
|
Director
|
February 19, 2019
|
|
Susan M. Stalnecker
|
||
|
|
|
|
|
/s/ Noel B. Williams
|
Director
|
February 19, 2019
|
|
Noel B. Williams
|
||
No information found
* THE VALUE IS THE MARKET VALUE AS OF THE LAST DAY OF THE QUARTER FOR WHICH THE 13F WAS FILED.
| FUND | NUMBER OF SHARES | VALUE ($) | PUT OR CALL |
|---|
| DIRECTORS | AGE | BIO | OTHER DIRECTOR MEMBERSHIPS |
|---|
No information found
No Customers Found
No Suppliers Found
Price
Yield
| Owner | Position | Direct Shares | Indirect Shares |
|---|